Anti-RANTES antibodies

ABSTRACT

The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.

RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No.12/221,485, filed on Aug. 4, 2008, now issued as U.S. Pat. No.8,012,474, which claims the benefit of U.S. Provisional Application No.60/963,271, filed Aug. 2, 2007, the contents of which are herebyincorporated by reference in their entirety.

INCORPORATION OF SEQUENCE LISTING

The contents of the text file named “414C01USSeqList.txt”, which wascreated on Aug. 11, 2011 and is 116 KB in size, are hereby incorporatedby reference in their entirety.

FIELD OF THE INVENTION

This invention relates generally to fully human monoclonal antibodiesthat bind to RANTES (Regulated upon Activation, Normal T-cell Expressed,and Secreted) as well as to methods for use thereof.

BACKGROUND OF THE INVENTION

RANTES (Regulated upon Activation, Normal T-cell Expressed, andSecreted, CCL5) is a chemokine that is a chemoattractant foreosinophils, monocytes, and lymphocytes.

Elevated levels of RANTES expression has been implicated in a variety ofdiseases and disorders. Accordingly, there exists a need for therapiesthat target RANTES activity.

SUMMARY OF THE INVENTION

The present invention provides monoclonal antibodies, such as fullyhuman monoclonal antibodies, that specifically bind Regulated uponActivation, Normal T-cell Expressed, and Secreted (RANTES, also referredto herein as CCL5). Exemplary monoclonal antibodies include theantibodies referred to herein as 1D9, 1E4, C8, 3E7, 4D8, 5E1, 6A8, 7B5,CG11, BG11, A9, E6, H6, G2, E 10, C10, 2D1, A5, H11, D1 and/or E7.Alternatively, the monoclonal antibody is an antibody that binds to thesame epitope as 1D9, 1E4, C8, 3E7, 4D8, 5E1, 6A8, 7B5, CG11, BG11, A9,E6, H6, G2, E10, C10, 2D1, A5, H11, D1 and/or E7. The antibodies arerespectively referred to herein as huRANTES antibodies. huRANTESantibodies include fully human monoclonal antibodies, as well ashumanized monoclonal antibodies and chimeric antibodies.

huRANTES antibodies of the invention also include antibodies thatinclude a heavy chain variable amino acid sequence that is at least 90%,92%, 95%, 97%, 98%, 99% or more identical the amino acid sequence of SEQID NO: 2, 18, 22, 38, 48, 52, 56, 60, 68, 84, 100, 116, 132, 148, 164,180, 200, 216, 232, or 248 and/or a light chain variable amino acid thatis at least 90%, 92%, 95%, 97%, 98%, 99% or more identical the aminoacid sequence of SEQ ID NO: 4, 24, 40, 62, 70, 86, 102, 118, 134, 150,166, 182, 196, 202, 218, 234, or 250.

Preferably, the three heavy chain complementarity determining regions(CDRs) include an amino acid sequence at least 90%, 92%, 95%, 97%, 98%,99% or more identical to each of: (i) a VH CDR1 sequence selected fromSEQ ID NO: 8, 28, 44, 74, 90, 106, 122, 138, 154, and 222; (ii) a VHCDR2 sequence selected from SEQ ID NO: 9, 29, 45, 75, 91, 107, 123, 139,155, 207, 223, 239, and 255; (iii) a VH CDR3 sequence selected from SEQID NOs: 10, 20, 30, 46, 50, 54, 58, 64, 76, 92, 108, 124, 140, 156, 169,188, 208, 224, and 240; and a light chain with three CDR that include anamino acid sequence at least 90%, 92%, 95%, 97%, 98%, 99% or moreidentical to each of (iv) a VL CDR1 sequence selected from SEQ ID NO:14, 34, 77, 96, 112, 128, 144, 160, 176, 190, 192, 212, 228, and 244;(v) a VL CDR2 sequence selected from SEQ ID NO: 15, 35, 81, 97, 113,129, 145, 161, 177, 191, 193, 213, 229, and 245; and (vi) a VL CDR3sequence selected from SEQ ID NO: 16, 36, 66, 82, 98, 114, 130, 146,162, 178, 194, 214, 230, 235 and 246.

Preferably, the huRANTES antibodies are formatted in an IgG isotype.More preferably, the huRANTES antibodies are formatted in an IgG1isotype.

Exemplary IgG1-formatted antibody are the IgG1-formatted 1D9, 1E4 and C8antibodies comprising the heavy chain sequence and light chain sequenceshown below, and the CDR sequences are shown in boxes:

> 1D9 Heavy chain amino acid sequence (SEQ ID NO: 167)

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > 1D9 Light chain amino acid sequence (SEQ ID NO: 168)

LQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS >1E4 Heavy chain amino acid sequence (SEQ ID NO: 238)

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > 1E4 Light chain amino acid sequence (SEQ ID NO: 254)

LQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS >C8 Heavy chain amino acid sequence (SEQ ID NO: 186)

GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > C8 Light chain amino acid sequence (SEQ ID NO: 187)

LQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

The closest germline for the huRANTES antibodies described herein areshown below in Table 1:

TABLE 1 Closest germlines for the huRANTES antibodies. Antibodies markedin italic were derived by an affinity maturation process from antibody2D1 (Lower part of the table). Clone ID VH dp number VL dp number CG11Vh1_DP-3_(1-f) Vlambda1_DPL8_(1e) BG11 Vh1_DP-5_(1-24)Vlambda3_DPL16_(3l A9 Vh3_DP-47_(3-23) Vlambda6_6a E6 Vh1_DP-5_(1-24)Vlambda6_6a H6 Vh1_DP-5_(1-24) Vlambda1_DPL8_(1e) G2 Vh1_DP-5_(1-24)Vlambda2_DPL11_(2a2) El 0 Vh3_DP-46_(3-30.3) Vlambda3_3h C10Vh3_DP-47_(3-23) Vlambda3_3h 2D1 Vh1_DP-5_(1-24) Vlambda3_3h A5Vh1_DP-5_(1-24) Vlambda3_3h H11 Vh1_DP-1 0_(1-69) Vlambda1_DPL8_(1e) D1Vh1_DP-3_(1-f) Vlambda1_DPL8_(1e) E7 Vh 1_DP-10_(1-69)Vlambda1_DPL9_(1f) C8 Vh3_DP-46_(3-30.3) Vlambda3_3h 1D9 Vh1_DP-5_(1-24)Vlambda3_3h 1E4 Vh1_DP-5_(1-24) Vlambda3_3h 3E7 Vh1_DP-5_(1-24)Vlambda3_3h 4D8 Vh1_DP-5_(1-24) Vlambda3_3h 5E1 Vh1_DP-5_(1-24)Vlambda3_3h 6A8 Vh1_DP-5_(1-24) Vlambda3_3h 7B5 Vh1_DP-5_(1-24)Vlambda3_3h

The invention also provides antibodies that bind human RANTES when humanRANTES is bound to glycosaminoglycan (GAG), i.e., bind human RANTES inthe context of GAG. In a preferred embodiment, these antibodies include(a) a V_(H) CDR1 region comprising the amino acid sequence of SEQ ID NO:8, 28, 44, 90, 106, 122 or 154; (b) a V_(H) CDR2 region comprising theamino acid sequence of SEQ ID NO: 9, 29, 45, 91, 107, 123, 155, or 207;(c) a V_(H) CDR3 region comprising the amino acid sequence of SEQ ID NO:10, 20, 30, 64, 92, 124, 156, 188, or 208, (d) a V_(L) CDR1 regioncomprising the amino acid sequence of SEQ ID NO: 14, 34, 96, 128, 160,176, 192, or 212; (e) a V_(L) CDR2 region comprising the amino acidsequence of SEQ ID NO: 15, 35, 97, 129, 161, 177, 193, or 213; and (f) aV_(L) CDR3 region comprising the amino acid sequence of SEQ ID NO: 16,36, 98, 130, 162, 178, 194, or 214.

In some embodiments, the antibody is a monoclonal antibody or anantigen-binding fragment thereof. In some embodiments, the antibody is afully human monoclonal antibody or an antigen-binding fragment thereof.In some embodiments, the antibody is an IgG isotype, such as, forexample, an IgG1 isotype.

The invention also provides antagonist molecules of human RANTES, and inparticular, antagonists of human RANTES proteins, polypeptides and/orpeptides that include at least amino acid residues 16-18 of the matureamino acid sequence of human RANTES, e.g., SEQ ID NO: 170 shown in FIG.6. The anti-human RANTES antagonists bind to, or otherwise interactwith, a human RANTES protein, polypeptide, and/or peptide to modulate,e.g., reduce, inhibit or otherwise interfere, partially or completelywith a biological function of a human RANTES protein, such as forexample, the binding of RANTES to a receptor such as CCR1, CCR3, CCR4and/or CCR5, or the binding of RANTES to glycosaminoglycans (GAG).

In a preferred embodiment, the ability of the anti-human RANTESantagonists to bind to, or otherwise interact with, human RANTES proteinto modulate one or more biological functions of human RANTES isdependent upon the presence of amino acid residues 16-18 of the maturehuman RANTES sequence such as SEQ ID NO: 170. In this embodiment, theantagonist molecules do not bind a human RANTES polypeptide that lacksamino acid residues 16-18 of SEQ ID NO: 170.

The anti-RANTES antagonist molecules provided herein completely orpartially reduce or otherwise modulate RANTES expression or activityupon binding to, or otherwise interacting with, human RANTES. Thereduction or modulation of a biological function of RANTES is completeor partial upon interaction between the antagonist and the human RANTESprotein, polypeptide and/or peptide. The anti-huRANTES antagonists areconsidered to completely inhibit RANTES expression or activity when thelevel of RANTES expression or activity in the presence of theanti-huRANTES antagonist is decreased by at least 95%, e.g., by 96%,97%, 98%, 99% or 100% as compared to the level of RANTES expression oractivity in the absence of interaction, e.g., binding with ananti-huRANTES antagonist described herein. The anti-huRANTES antagonistsare considered to partially inhibit RANTES expression or activity whenthe level of RANTES expression or activity in the presence of theanti-huRANTES antagonist is decreased by less than 95%, e.g., 10%, 20%,25%, 30%, 40%, 50%, 60%, 75%, 80%, 85% or 90% as compared to the levelof RANTES expression or activity in the absence of interaction, e.g.,binding with an anti-huRANTES antagonist described herein.

In some embodiments, the anti-RANTES antagonist molecule is selectedfrom a small molecule inhibitor; a polypeptide, a peptide, aRANTES-derived mutant polypeptide, a RANTES-derived polypeptide variant,a RANTES receptor-derived mutant polypeptide, e.g., a mutated CCR1,CCR3, CCR4 or CCR5 protein, polypeptide or peptide, a RANTESreceptor-derived polypeptide variant, e.g., a CCR1, CCR3, CCR4 or CCR5variant peptide, polypeptide or protein, and a nucleic acid-basedantagonist.

In some embodiments, the anti-RANTES antagonist molecule is an isolatedmonoclonal anti-human RANTES antibody or antigen-binding fragmentthereof. Preferably, the antibody (or antigen-binding fragment thereof)binds to amino acid residues 16-18 of the mature amino acid sequence ofhuman RANTES, e.g., SEQ ID NO: 170 shown in FIG. 6. In some embodiments,the anti-RANTES antibody is a fully human monoclonal anti-human RANTESantibody or antigen-binding fragment thereof. In some embodiments, theantibody is an IgG isotype, such as an IgG1 isotype.

In some embodiments, the anti-RANTES antagonist molecule is a mutatedRANTES polypeptide or RANTES-derived variant polypeptide or a mutatedRANTES receptor, for example, selected from CCR1, CCR3, CCR4, and CCR5,or a variant of a RANTES receptor polypeptide, such as CCR1, CCR3, CCR4,or CCR5, that modulates an activity of RANTES selected from the abilityof RANTES to bind to a receptor selected from CCR1, CCR3, CCR4, andCCR5, the ability of RANTES to bind a glycosaminoglycan and the abilityof RANTES to form oligomers.

In some embodiments, the anti-RANTES antagonist molecule is a nucleicacid-based antagonist such as, for example, an aptamer or otheroligonucleotide capable of interacting with targets, such as proteins,polypeptides, small molecules, carbohydrates, peptides or any otherbiological molecules, through interactions other than Watson-Crick basepairing.

The invention also provides methods of treating, preventing, alleviatinga symptom of, or otherwise mitigating ischemia, a clinical indicationassociated with ischemia and/or reperfusion injury in a subject. Theinvention is based on the discovery that modulation, particularly,inhibition or other reduction of RANTES expression or activity inhibitsischemia and/or reperfusion injury in an animal model for ischemia andreperfusion. Accordingly, the invention provides methods of preventingor inhibiting ischemia, a clinical indication associated with ischemia,reperfusion injury, in a subject, in a bodily tissue and/or in a tissueor organ to be transplanted. In the methods provided herein, the subjectto be treated is administered an antagonist of RANTES. Likewise, in thetreatment of organs to be transplanted, the organ, or a portion thereof,is contacted with an antagonist of RANTES. The methods provided hereinare useful in vivo and ex vivo.

Suitable antagonists of RANTES include any antibody or fragment thereofthat inhibits, neutralizes or otherwise interferes with the expressionand/or activity of RANTES, such as, e.g., the huRANTES antibodiesprovided herein; small molecule inhibitors; proteins, polypeptides,peptides; protein-, polypeptide- and/or peptide-based antagonists suchas RANTES mutants and/or other RANTES variants and or RANTESreceptor-based mutants and/or variants, such as, for example, mutated orvariant versions of CCR1, CCR3, CCR4 or CCR5 polypeptides; nucleic acidbased antagonists such as siRNA and/or anti-sense RNA, and/or aptamers;and/or fragments thereof that inhibit, neutralize or otherwise interferewith the expression and/or activity of RANTES.

Examples of polypeptide-based antagonists of RANTES include modifiedvariants of RANTES that inhibit, neutralize or otherwise interfere withthe expression and/or activity of RANTES. Variants of RANTES that areknown to antagonize RANTES, for example, by decreasing the ability ofRANTES to bind to glycosaminoglycans (GAG), include the RANTES mutantsand variants described in PCT Publication Nos. WO 2004/062688; WO2003/0844562; WO 2003/051921; WO 2002/028419; WO 2000/016796 and WO1996/017935, each of which is hereby incorporated by reference in itsentirety.

Examples of nucleic acid-based antagonists of RANTES include shortinterfering RNA (siRNA) mediated gene silencing where expressionproducts of a RANTES gene are targeted by specific double strandedRANTES derived siRNA nucleotide sequences that are complementary to asegment of the RANTES gene transcript, e.g., at least 19-25 nucleotideslong, including the 5′ untranslated (UT) region, the ORF, or the 3′ UTregion. See, e.g., PCT applications WO00/44895, WO99/32619, WO01/75164,WO01/92513, WO 01/29058, WO01/89304, WO02/16620, and WO02/29858, eachincorporated by reference herein in their entirety. Nucleic-acid basedantagonists of RANTES also include antisense nucleic acids. An antisensenucleic acid comprises a nucleotide sequence that is complementary to a“sense” nucleic acid encoding a RANTES protein or fragment thereof. Forexample, antisense RANTES antagonists comprise a sequence complementaryto at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entireRANTES coding strand, or to only a portion thereof.

Preferably, the RANTES antagonist inhibits, partially or completely, afunction of RANTES selected from the ability of RANTES to bind to acorresponding receptor (e.g., CCR1, CCR3, CCR4, and/or CCR5), theability of RANTES to bind glycosaminoglycans and/or the ability ofRANTES to form oligomers. Suitable RANTES antagonists are identified,for example, using the assays and models provided in the Examples below.

The anti-huRANTES antagonists are considered to completely inhibitRANTES expression or activity when the level of RANTES expression oractivity in the presence of the anti-huRANTES antagonist is decreased byat least 95%, e.g., by 96%, 97%, 98%, 99% or 100% as compared to thelevel of RANTES expression or activity in the absence of interaction,e.g., binding with an anti-huRANTES antagonist described herein. Theanti-huRANTES antagonists are considered to partially inhibit RANTESexpression or activity when the level of RANTES expression or activityin the presence of the anti-huRANTES antagonist is decreased by lessthan 95%, e.g., 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85% or 90%as compared to the level of RANTES expression or activity in the absenceof interaction, e.g., binding with an anti-huRANTES antagonist describedherein.

In one aspect, the invention provides methods of treating, preventing oralleviating a symptom of ischemia or a clinical indication associatedwith ischemia by administering a RANTES antagonist, such as a huRANTESantibody, to a subject in need thereof or by contacting an organ in needthereof with a RANTES antagonist, such as a huRANTES antibody. Theischemia to be treated includes cardiac ischemia, cerebral ischemia,renal ischemia, and related ischemic diseases or events. Clinicalindications associated with ischemia and reperfusion include, forexample, coronary artery disease, cerebral vascular disease, cardiacischemia, myocardial ischemia, renal ischemia and peripheral vasculardisease. Ischemia is a feature of heart diseases includingatherosclerosis, myocardial infarction, transient ischemic attacks,cerebrovascular accidents, ruptured arteriovenous malformations, andperipheral artery occlusive disease. The heart, the kidneys, and thebrain are among the organs that are the most sensitive to inadequateblood supply. Ischemia in brain tissue is due, for example, to stroke orhead injury. Use of a RANTES antagonist, such as a huRANTES antibody, isalso envisioned as part of a protocol for optimizing tissue healthduring extra-corporeal perfusion of organs and/or tissue prior totransplantation, including, for example, heart, lung, and kidney. Theorgans to be treated using the methods provided herein are contacted invivo or ex vivo.

The antibodies and compositions provided herein are useful in treating,preventing or otherwise delaying the progression of tissue injury orother damage caused by ischemia or a clinical indication associated withischemia. For example, a huRANTES antibody or other RANTES antagonist ofthe invention is administered to a subject in need thereof before anischemic event, during an ischemic event, after an ischemic event or anycombination thereof.

The antibodies, RANTES antagonists and compositions provided herein arealso useful in methods of treating, preventing or alleviating a symptomof a reperfusion injury or other tissue damage that occurs in a subjectwhen blood supply returns to a tissue site after a period of ischemia.For example, a RANTES antagonist, such as a huRANTES antibody of theinvention, is administered to a subject in need thereof, e.g., during anischemic event, after an ischemic event or both during and after anischemic event. In some cases, restoration of blood flow after a periodof ischemia can be more damaging than the ischemia. Reintroduction ofoxygen causes a greater production of damaging free radicals, resultingin reperfusion injury. With reperfusion injury, tissue damage and/ornecrosis can be greatly accelerated. Reperfusion injuries to be treatedor prevented include injuries caused by an inflammatory response in thedamaged tissue or tissues.

The subject or organ to be transplanted is suffering from or ispredisposed to developing ischemia, an ischemic-related disorder, and/orreperfusion related tissue damage. Preferably, the subject is a mammal,and more preferably, the subject is a human.

In another aspect, the invention provides methods of treating,preventing or alleviating a symptom of an immune-related disorder byadministering a huRANTES antibody to a subject. For example, thehuRANTES antibodies are used to treat, prevent or alleviate a symptomassociated with an autoimmune disease or inflammatory disorder.Optionally, the subject is further administered with a second agent suchas, but not limited to, an anti-cytokine reagent, anti-chemokinereagent, an anti-cytokine reagent or an anti-chemokine receptor thatrecognizes the ligand or receptor for proteins such as interleukin 1(IL-1), IL-2, IL-4, IL-6, IL-12, IL-13, IL-15, IL-17, IL-18, IL-20,IL-21, IL-22, IL-23, IL-27, IL-31, MIP1 alpha, MIP1 beta, IP-10, MCP1,ITAC, MIG, SDF and fractalkine.

The subject is suffering from or is predisposed to developing an immunerelated disorder, such as, for example, an autoimmune disease or aninflammatory disorder. Preferably, the subject is a mammal, and morepreferably, the subject is a human.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a series of graphs depicting the activity of anti-huRANTESantibodies in chemotaxis assays using L1.2 cells transfected with hCCR5and 1 nM or 0.2 nM of recombinant human RANTES (FIGS. 1A and Brespectively) as well as native human RANTES (FIGS. 1C).

FIG. 2 is a graph depicting the capacity of anti-huRANTES antibodies tobind to huRANTES in the context of glycosaminoglycans in and ELISAassay.

FIG. 3 is a series of graphs depicting the activity of anti-huRANTESantibody 1E4 in calcium flux assays using: L1.2 cells expressing hCCR1and 25 nM recombinant human RANTES (FIG. 3A); L1.2 cells expressinghCCR3 and 25 nM recombinant human RANTES (FIG. 3B); L1.2 cellsexpressing hCCR5 and 4 nM recombinant human RANTES (FIG. 3C).

FIG. 4 is a series of graphs depicting the activity of anti-huRANTESantibody 1E4 in chemotaxis assays using: L1.2 cells expressing hCCR1 and2 nM of recombinant human RANTES (FIG. 4A); L1.2 cells expressing hCCR3and 10 nM of recombinant human RANTES (FIG. 4B); L1.2 cells expressinghCCR5 and 1 nM of recombinant human RANTES (FIG. 4C); L1.2 cellsexpressing hCCR5 and about 1 nM of native human RANTES (FIG. 4D).

FIG. 5 is a graph depicting the cross-reactivity profile of antibody 1E4against a panel of human, cynomolgus, mouse and rat chemokines in anELISA.

FIG. 6 is a sequence alignment of mature RANTES protein from human (SEQID NO: 170), cynomolgus monkey (SEQ ID NO: 171), mouse (SEQ ID NO: 172)and rat (SEQ ID NO: 206). The arrows indicate positions that areconserved in human and cynomolgus RANTES but not in the mouse or ratsequences and that were targeted by site-directed mutagenesis.

FIG. 7 is a graph depicting the binding of antibody 1E4 (open bars) orof a polyclonal antibody raised against mouse RANTES (hatched bars) tohuman RANTES, mouse RANTES and variants of mouse RANTES in which theindicated mouse amino acids have been replaced by the amino acids foundin the human sequence at the same position.

FIG. 8 is an illustration depicting the protocol of a murine ischemiareperfusion model provided herein.

FIG. 9 is a series of graphs depicting that anti-RANTES treatmentdecreased infarct size in a murine model of ischemia reperfusion. Thedata represents 20 mice per group.

FIG. 10 is a series of graphs depicting that anti-RANTES treatmentdecreased infarct size in a murine model of ischemia reperfusion in adose-dependent manner. Data represents 3 mice per group.

FIG. 11 is an illustration depicting the protocol of a murine ischemiamodel provided herein.

FIG. 12 is a series of graphs depicting that anti-RANTES treatmentdecreased infarct size in a murine model of ischemia. The datarepresents 10 mice per group.

FIG. 13 is a series of graphs depicting that anti-RANTES treatmentdecreased infarct size in a murine model of ischemia in a dose-dependentmanner. Data represents 3 mice per group.

DETAILED DESCRIPTION

The present invention provides fully human monoclonal antibodiesspecific for the chemokine Regulated upon Activation, Normal T-cellExpressed, and Secreted (RANTES, CCL5). The terms “RANTES” and “CCL5”are used interchangeably herein. The antibodies are collectivelyreferred to herein as huRANTES antibodies. The huRANTES antibodiesspecifically bind RANTES. As used herein, the terms “specific for”,“specific binding”, “directed against” (and all grammatical variationsthereof) are used interchangeably in the context of antibodies thatrecognize and bind to a RANTES epitope when the equilibrium bindingconstant (K_(d)) is ≦1 μM, e.g., ≦100 nM, preferably ≦10 nM, and morepreferably ≦1 nM. For example, the huRANTES antibodies provided hereinexhibit a K_(d) in the range approximately between ≦10 nM to about 100pM.

The huRANTES antibodies are, for example, RANTES antagonists orinhibitors that modulate at least one biological activity of RANTES.Biological activities of RANTES include, for example, binding a RANTESreceptor such as, for example, CCR1, CCR3, CCR4, and/or CCR5;chemoattraction of eosinophils, monocytes, and lymphocytes; binding ofRANTES to glycosaminoglycans as well as RANTES oligomerization. Forexample, the huRANTES antibodies completely or partially inhibit RANTESactivity by partially or completely blocking the binding of RANTES to aRANTES receptor (e.g., CCR1, CCR3, CCR4, and/or CCR5). The RANTESantibodies are considered to completely inhibit RANTES activity when thelevel of RANTES activity in the presence of the huRANTES antibody isdecreased by at least 95%, e.g., by 96%, 97%, 98%, 99% or 100% ascompared to the level of RANTES activity in the absence of binding witha huRANTES antibody described herein. The RANTES antibodies areconsidered to partially inhibit RANTES activity when the level of RANTESactivity in the presence of the huRANTES antibody is decreased by lessthan 95%, e.g., 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85% or 90%as compared to the level of RANTES activity in the absence of bindingwith a huRANTES antibody described herein.

The huRANTES antibodies of the invention are produced by immunizing ananimal with RANTES, such as, for example, murine or human RANTES or animmunogenic fragment, derivative or variant thereof. Alternatively, theanimal is immunized with cells transfected with a vector containing anucleic acid molecule encoding RANTES, such that RANTES is expressed andassociated with the surface of the transfected cells. Alternatively, theantibodies are obtained by screening a library that contains antibody orantigen binding domain sequences for binding to RANTES. This library isprepared, e.g., in bacteriophage as protein or peptide fusions to abacteriophage coat protein that is expressed on the surface of assembledphage particles and the encoding DNA sequences contained within thephage particles (i.e., “phage displayed library”).

huRANTES antibodies of the invention include, for example, the heavychain complementarity determining regions (CDRs) shown below in Table 2,the light chain CDRs shown in Table 3, and combinations thereof.

TABLE 2 VH CDR sequences from antibody clones that bind andneutralize RANTES. Antibodies marked in italic werederived by an affinity maturation process fromantibody 2D1 (Lower part of the table). Clone ID Heavy CDR1 Heavy CDR2Heavy CDR3 CG11 DYYIH LIDPKDGEIQYAEKFQA EVLSGIRVFPFDP (SEQ NO: 74)(SEQ NO: 75) (SEQ NO: 76) BG11 ELSMH GFDPEDGETIYAQKFQG YSGSSGWWAFDI(SEQ NO: 90) (SEQ NO: 91) (SEQ NO: 92) A9 SYAMS AISGSGGSTYYADSVKGDLGYCTNGVCWGIDY (SEQ NO: 106) (SEQ NO: 107) (SEQ NO: 108) E6 EIAIHSFEPEDAEAIYAQRFQG DPYYASSGSNYMEV (SEQ NO: 122) (SEQ NO: 123)(SEQ NO: 124) H6 KQSMH SSNPEDDETLYAKKFQG DSQGFYYYYGMDV (SEQ NO: 138)(SEQ NO: 139) (SEQ NO: 140) G2 ELSIH GFDPEDGETIYAQNFQG DLTGSRDS(SEQ NO: 154) (SEQ NO: 155) (SEQ NO: 156) E10 SYAMH VISYDGSNKYYADSVKGETFPHYYYYYMDV (SEQ NO: 28) (SEQ NO: 29) (SEQ NO: 30) C10 SYAMSAISGSGGSTYYADSVKG VRGSSQYDFWSGSEFDY (SEQ NO: 106) (SEQ NO: 107)(SEQ NO: 188) 2D1 DFAMH GYVPEDGDTIYAQKFQG DPLYSGSLSY (SEQ NO: 44)(SEQ NO: 45) (SEQ NO: 64) A5 ELSIH YIDPEDGEPIYAQKFQG VTGSTSDAFDL(SEQ NO: 154) (SEQ NO: 207) (SEQ NO: 208) H11 NYALS GFIPLVDTTNYAQRFQGEQVAVGPGPTSDRGPDGLDV (SEQ NO: 222) (SEQ NO: 223) (SEQ NO: 224) D1 DYYIHLVDSEEDGETLFAETFRG EYGEYGFFQS (SEQ NO: 74) (SEQ NO: 239) (SEQ NO: 240)E7 NYALS AVIPLVETTSYAQRFQG EQVAVGPGPTSNRGPDGLDV (SEQ NO: 222)(SEQ NO: 255) (SEQ NO: 169) C8 SYAMH VISYDGSNKYYADSVKG ETFPHYYYYYMDV(SEQ NO: 28) (SEQ NO: 29) (SEQ NO: 30) 1D9 EFAMH GFVPEDGETIYAQKFQGDPLYPPGLEP (SEQ NO: 8) (SEQ NO: 9) (SEQ NO: 10) 1E4 EFAMHGFVPEDGETIYAQKFQG DPLYEGSFSV (SEQ NO: 8) (SEQ NO: 9) (SEQ NO: 20) 3E7DFAMH GYVPEDGDTIYAQKFQG DPLYPPGLSP (SEQ NO: 44) (SEQ NO: 45)(SEQ NO: 46) 4D8 DFAMH GYVPEDGDTIYAQKFQG DPLYTPGLYV (SEQ NO: 44)(SEQ NO: 45) (SEQ NO: 50) 5E1 DFAMH GYVPEDGDTIYAQKFQG DYLYIPSLSY(SEQ NO: 44) (SEQ NO: 45) (SEQ NO: 54) 6A8 DFAMH GYVPEDGDTIYAQKFQGDPLYPPGLQP (SEQ NO: 44) (SEQ NO: 45) (SEQ NO: 58) 7B5 DFAMHGYVPEDGDTIYAQKFQG DPLYSGSLSY (SEQ NO: 44) (SEQ NO: 45) (SEQ NO: 64)

TABLE 3 VL CDR sequences from antibody clones that  bind and neutralize RANTES. Antibodies  marked in italic were derived by an affinity maturation process from antibody 2D1   (Lower part of the table). Clone ID Light CDR1 Light CDR2 Light CDR3 CG11 TGSSSNIGAGYDVY DTNNRPPQSYDIALSNSNVV (SEQ NO: 77) (SEQ NO: 81) (SEQ NO: 82) BG11 QGDSLRSYYASGKNNRPS QTWGTGIWV (SEQ NO: 96) (SEQ NO: 97) (SEQ NO: 98) A9TRSSGSIADNYVQ DDDQRLS QSYDDSNDV (SEQ NO: 112) (SEQ NO: 113)(SEQ NO: 114) E6 TGSGGSISSNYVQ EDDQRPS HSYDGNNRWV (SEQ NO: 128)(SEQ NO: 129) (SEQ NO: 130) H6 TGSSSNIGADYDVH DNINRPS QSYDSSLSGVL(SEQ NO: 144) (SEQ NO: 145) (SEQ NO: 146) G2 TGSRSDIGYYNYVS DVTERPSSSFSSGDTFVV (SEQ NO: 160) (SEQ NO: 161) (SEQ NO: 162) E10 GGGNFDDEGVHDDTGRPS QAWDSSNDHPV (SEQ NO: 176) (SEQ NO: 177) (SEQ NO: 178) C10GGDNIGGQNVH YDTDRPS QVWDVDSDHPWV (SEQ NO: 192) (SEQ NO: 193)(SEQ NO: 194) 2D1 GGNNIESKSVH DDSDRPS QVWDSNTDHWV (SEQ NO: 14)(SEQ NO: 15) (SEQ NO: 16) A5 GGANLWGLGVH DNSDRAS QVWDSSSDHWV(SEQ NO: 212) (SEQ NO: 213) (SEQ NO: 214) H11 TGSNSNLGADYDVH DNNIRPSQSYDTGLTSSDVI (SEQ NO: 228) (SEQ NO: 229) (SEQ NO: 230) D1TGSSSNIGADYDVN GDINRPS QSFDNSLSGSVI (SEQ NO: 244) (SEQ NO: 245)(SEQ NO: 246) E7 TGSSSNIGDGYDVH GNSNRPS GTWDDILNGWV (SEQ NO: 190)(SEQ NO: 191) (SEQ NO: 235) C8 EGDDTDIGTVN EDGYRPS QFWDVDSDHPV(SEQ NO: 34) (SEQ NO: 35) (SEQ NO: 36) 1D9 GGNNIESKSVH DDSDRPSQVWDSNTDHWV (SEQ NO: 14) (SEQ NO: 15) (SEQ NO: 16) 1E4 GGNNIESKSVHDDSDRPS QVWDSNTDHWV (SEQ NO: 14) (SEQ NO: 15) (SEQ NO: 16) 3E7GGNNIESKSVH DDSDRPS QVWDSNTDHWV (SEQ NO: 14) (SEQ NO: 15) (SEQ NO: 16)4D8 GGNNIESKSVH DDSDRPS QVWDSNTDHWV (SEQ NO: 14) (SEQ NO: 15)(SEQ NO: 16) 5E1 GGNNIESKSVH DDSDRPS QVWDSNTDHWV (SEQ NO: 14)(SEQ NO: 15) (SEQ NO: 16) 6A8 GGNNIESKSVH DDSDRPS QVWDSNTDHWV(SEQ NO: 14) (SEQ NO: 15) (SEQ NO: 16) 7B5 GGNNIESKSVH DDSDRPSQVWDSGPVWWI (SEQ NO: 14) (SEQ NO: 15) (SEQ NO: 66)

An exemplary huRANTES monoclonal antibody is the 1D9 antibody describedherein. As shown below, the 1D9 antibody includes a heavy chain variableregion (SEQ ID NO:2) encoded by the nucleic acid sequence shown in SEQID NO:1, and a light chain variable region (SEQ ID NO:4) encoded by thenucleic acid sequence shown in SEQ ID NO:3. The CDR sequences are shownin boxes.

> 1D9 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 1):CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCC

> 1D9 Heavy chain variable domain amino acid sequence (SEQ ID NO: 2)

> D9 Light chain variable domain nucleic acid sequence (SEQ ID NO: 3):TCCTATGTGCTGACTCAGCCACCCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACC

TCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGAC

ACCGTCCTA>1 D9 Light chain variable domain amino acid sequence (SEQ ID NO: 4)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 1D9 antibody have the followingsequences: EFAMH (SEQ ID NO:8), encoded by the nucleic acid sequenceGAGTTCGCCATGCAC (SEQ ID NO: 5); GFVPEDGETIYAQKFQG (SEQ ID NO:9), encodedby the nucleic acid sequenceGGTTTTGTTCCTGAAGATGGTGAGACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 6); andDPLYTPGLEP (SEQ ID NO:10), encoded by the nucleic acid sequenceGATCCCCTGTATACTCCGGGTCTTGAGCCT (SEQ ID NO: 7). The light chain CDRs ofthe 1D9 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 13).

An exemplary huRANTES monoclonal antibody is the 1E4 antibody describedherein. As shown below, the 1E4 antibody includes a heavy chain variableregion (SEQ ID NO:18) encoded by the nucleic acid sequence shown in SEQID NO:17, and a light chain variable region (SEQ ID NO: 4) encoded bythe nucleic acid sequence shown in SEQ ID NO:3. The CDR sequences areshown in boxes.

> 1E4 Heavy Chain variable domain nucleic acid sequence (SEQ ID NO: 17):CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCC

> 1E4 Heavy chain variable domain amino acid sequence (SEQ ID NO: 18)

> 1E4 Light chain nucleic acid sequence (SEQ ID NO: 3):TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACC

TCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGAC

ACCGTCCTA >1E4 Light chain variable domain amino acid sequence (SEQ ID NO: 4)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 1E4 antibody have the followingsequences: EFAMH (SEQ ID NO:8), encoded by the nucleic acid sequenceGAGTTCGCCATGCAC (SEQ ID NO: 5); GFVPEDGETIYAQKFQG (SEQ ID NO:9), encodedby the nucleic acid sequenceGGTTTTGTTCCTGAAGATGGTGAGACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 6); andDPLYEGSFSV (SEQ ID NO:20), encoded by the nucleic acid sequenceGATCCCCTGTATGAGGGTCCGTTTTCTGTT (SEQ ID NO: 19). The light chain CDRs ofthe 1E4 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 13).

An exemplary huRANTES monoclonal antibody is the C8 antibody describedherein. As shown below, the C8 antibody includes a heavy chain variableregion (SEQ ID NO:22) encoded by the nucleic acid sequence shown in SEQID NO: 21, and a light chain variable region (SEQ ID NO:24) encoded bythe nucleic acid sequence shown in SEQ ID NO: 23. The CDR sequences areshown in boxes.

> C8 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 21)CAGGTGCAGCTGGTGGAGTCTGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCC

> C8 Heavy chain variable domain amino acid sequence (SEQ ID NO: 22)

> C8 Light chain variable domain nucleic acid sequence (SEQ ID NO: 23):TCCTATGTGCTGACTCAGCCCCCCTCGGTGTCAGTGGCCCCAGGGCAGACGGCCCGCATTACC

TCCAACTCTGGGAACACGGCCACCCTTACCATCTCCAGGGTCGAGGCCGGGGATGAGGCCGAC

ACCGTCCTA >C8 Light chain variable domain amino acid sequence (SEQ ID NO: 24)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the C8 antibody have the followingsequences: SYAMH (SEQ ID NO:28), encoded by the nucleic acid sequenceAGCTATGCTATGCAC (SEQ ID NO: 25); VISYDGSNKYYADSVKG (SEQ ID NO:29),encoded by the nucleic acid sequenceGTTATATCATATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGC (SEQ ID NO: 26); andETFPHYYYYYMDV (SEQ ID NO:30), encoded by the nucleic acid sequenceGAAACTTTCCCCCACTACTACTACTACTACATGGACGTC (SEQ ID NO: 27). The light chainCDRs of the C8 antibody have the following sequences: EGDDTDIGTVN (SEQID NO:34), encoded by the nucleic acid sequenceGAGGGAGACGACACTGACATTGGTACTGTCAAC (SEQ ID NO:31); EDGYRPS (SEQ IDNO:35), encoded by the nucleic acid sequence GAGGATGGCTACCGGCCCTCA (SEQID NO: 32); and QFWDVDSDHPV (SEQ ID NO:36), encoded by the nucleic acidsequence CAGTTCTGGGATGTTGACAGTGATCATCCGGTT (SEQ ID NO: 33).

An exemplary huRANTES monoclonal antibody is the 3E7 antibody describedherein. As shown below, the 3E7 antibody includes a heavy chain variableregion (SEQ ID NO:38) encoded by the nucleic acid sequence shown in SEQID NO: 37, and a light chain variable region (SEQ ID NO:40) encoded bythe nucleic acid sequence shown in SEQ ID NO: 39. The CDR sequences areshown in boxes.

> 3E7 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 37)CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT

> 3E7 Heavy chain variable domain amino acid sequence (SEQ ID NO: 38)

> 3E7 Light chain variable domain nucleic acid sequence (SEQ ID NO: 39):TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATT

TTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGG

GGAGGGACCAAGGTCACCGTCCTA >3E7 Light chain variable domain amino acid sequence (SEQ ID NO: 40)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 3E7 antibody have the followingsequences: DFAMH (SEQ ID NO:44), encoded by the nucleic acid sequenceGACTTCGCCATGCAC (SEQ ID NO: 41); GYVPEDGDTIYAQKFQG (SEQ ID NO:45),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 42); andDPLYPPGLSP (SEQ ID NO:46), encoded by the nucleic acid sequenceGATCCCCTGTATCCGCCTGGGCTGTCTCCT (SEQ ID NO: 43). The light chain CDRs ofthe 3E7 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 13).

An exemplary huRANTES monoclonal antibody is the 4D8 antibody describedherein. As shown below, the 4D8 antibody includes a heavy chain variableregion (SEQ ID NO:48) encoded by the nucleic acid sequence shown in SEQID NO: 47, and a light chain variable region (SEQ ID NO:40) encoded bythe nucleic acid sequence shown in SEQ ID NO: 39. The CDR sequences areshown in boxes.

> 4D8 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 47)CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT

> 4D8 Heavy chain variable domain amino acid sequence (SEQ ID NO: 48)

> 4D8 Light chain variable domain nucleic acid sequence (SEQ ID NO: 39):TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATT

TTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGG

GGAGGGACCAAGGTCACCGTCCTA >4D8 Light chain variable domain amino acid sequence (SEQ ID NO: 40)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 4D8 antibody have the followingsequences: DFAMH (SEQ ID NO:44), encoded by the nucleic acid sequenceGACTTCGCCATGCAC (SEQ ID NO: 41); GYVPEDGDTIYAQKFQG (SEQ ID NO:45),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 42); andDPLYTPGLYV (SEQ ID NO:50), encoded by the nucleic acid sequenceGATCCCCTGTATACGCCTGGTCTGTATGTG (SEQ ID NO: 49). The light chain CDRs ofthe 4D8 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 13).

An exemplary huRANTES monoclonal antibody is the 5E1 antibody describedherein. As shown below, the 5E1 antibody includes a heavy chain variableregion (SEQ ID NO:52) encoded by the nucleic acid sequence shown in SEQID NO: 51, and a light chain variable region (SEQ ID NO:40) encoded bythe nucleic acid sequence shown in SEQ ID NO: 39. The CDR sequences areshown in boxes.

> 5E1 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 51)CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT

> 5E1 Heavy chain variable domain amino acid sequence (SEQ ID NO: 52)

> 5E1 Light chain variable domain nucleic acid sequence (SEQ ID NO: 39):TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATT

TTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATCAGCAGGGTCGAAGCCGGG

GGAGGGACCAAGGTCACCGTCCTA >5E1 Light chain variable domain amino acid sequence (SEQ ID NO: 40)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 5E1 antibody have the followingsequences: DFAMH (SEQ ID NO:44), encoded by the nucleic acid sequenceGACTTCGCCATGCAC (SEQ ID NO: 41); GYVPEDGDTIYAQKFQG (SEQ ID NO:45),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 42); andDYLYIPSLSY (SEQ ID NO:54), encoded by the nucleic acid sequenceGATTATTTGTATATTCCTAGCTTATCCTAC (SEQ ID NO: 53). The light chain CDRs ofthe 5E1 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 13).

An exemplary huRANTES monoclonal antibody is the 6A8 antibody describedherein. As shown below, the 6A8 antibody includes a heavy chain variableregion (SEQ ID NO:56) encoded by the nucleic acid sequence shown in SEQID NO: 55, and a light chain variable region (SEQ ID NO:40) encoded bythe nucleic acid sequence shown in SEQ ID NO: 39. The CDR sequences areshown in boxes.

> 6A8 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 55)

> 6A8 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 56)

> 6A8 Light chain variable domain nucleic acid sequence (SEQ ID NO: 39):

> 6A8 Light chain variable domain amino acid sequence (SEQ ID NO: 40)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 6A8 antibody have the followingsequences: DFAMH (SEQ ID NO:44), encoded by the nucleic acid sequenceGACTTCGCCATGCAC (SEQ ID NO: 41); GYVPEDGDTIYAQKFQG (SEQ ID NO:45),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 42); andDPLYPPGLQP (SEQ ID NO:58), encoded by the nucleic acid sequenceGATCCCCTGTATCCTCCGGGGCTGCAGCCT (SEQ ID NO: 57). The light chain CDRs ofthe 6A8 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 13).

An exemplary huRANTES monoclonal antibody is the 7B5 antibody describedherein. As shown below, the 7B5 antibody includes a heavy chain variableregion (SEQ ID NO:60) encoded by the nucleic acid sequence shown in SEQID NO: 59, and a light chain variable region (SEQ ID NO:62) encoded bythe nucleic acid sequence shown in SEQ ID NO: 61. The CDR sequences areshown in boxes.

> 7B5 Heavy chain variable domain nucleic acid sequence  (SEQ ID NO: 59)

> 7B5 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 60)

> 7B5 Light chain variable domain nucleic acid sequence (SEQ ID NO: 61):

> 7B5 Light chain variable domain amino acid sequence (SEQ ID NO: 62)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 7B5 antibody have the followingsequences: DFAMH (SEQ ID NO:44), encoded by the nucleic acid sequenceGACTTCGCCATGCAC (SEQ ID NO: 41); GYVPEDGDTIYAQKFQG (SEQ ID NO:45),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 42); andDPLYSGSLSY (SEQ ID NO:64), encoded by the nucleic acid sequenceGATCCCCTGTATAGTGGGAGCTTATCCTAC (SEQ ID NO: 63). The light chain CDRs ofthe 7B5 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSGPVWWI (SEQ ID NO:66), encoded by the nucleic acidsequence TCAGGTGTGGGATAGTGGTCCTGTGTGGTGGATT (SEQ ID NO: 65).

An exemplary huRANTES monoclonal antibody is the CG11 antibody describedherein. As shown below, the CG11 antibody includes a heavy chainvariable region (SEQ ID NO:68) encoded by the nucleic acid sequenceshown in SEQ ID NO: 67, and a light chain variable region (SEQ ID NO:70)encoded by the nucleic acid sequence shown in SEQ ID NO: 69. The CDRsequences are shown in boxes.

> CG11 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 67)

> CG11 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 68)

> CG11 Light chain variable domain nucleic acid sequence (SEQ ID NO: 69):

> CG11 Light chain variable domain amino acid sequence  (SEQ ID NO: 70)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the CG11 antibody have the followingsequences: DYYIH (SEQ ID NO:74), encoded by the nucleic acid sequenceGACTACTACATACAC (SEQ ID NO: 71); LIDPKDGEIQYAEKFQA (SEQ ID NO:75),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 72); andEVLSGIRVFPFDP (SEQ ID NO:76), encoded by the nucleic acid sequenceGAGGTTTTAAGCGGTATTAGGGTTTTCCCATTCGACCCC (SEQ ID NO: 73). The light chainCDRs of the CG11 antibody have the following sequences: TGSSSNIGAGYDVY(SEQ ID NO:77), encoded by the nucleic acid sequenceACTGGGAGCAGCTCCAACATCGGGGCAGGTTATGATGTATAT (SEQ ID NO:80); DTNNRPP (SEQID NO:81), encoded by the nucleic acid sequence GATACCAACAATCGACCCCCA(SEQ ID NO: 78); and QSYDIALSNSNVV (SEQ ID NO:82), encoded by thenucleic acid sequence CAGTCTTATGACATCGCCCTGAGTAACTCGAATGTGGTT (SEQ IDNO: 79).

An exemplary huRANTES monoclonal antibody is the BG11 antibody describedherein. As shown below, the BG11 antibody includes a heavy chainvariable region (SEQ ID NO:84) encoded by the nucleic acid sequenceshown in SEQ ID NO: 83, and a light chain variable region (SEQ ID NO:86)encoded by the nucleic acid sequence shown in SEQ ID NO: 85. The CDRsequences are shown in boxes.

> BG11 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 83)

> BG11 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 84)

> BG11 Light chain variable domain nucleic acid sequence (SEQ ID NO: 85):

> BG11 Light chain variable domain amino acid sequence (SEQ ID NO: 86)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the BG11 antibody have the followingsequences: ELSMH (SEQ ID NO:90), encoded by the nucleic acid sequenceGAATTATCCATGCAC (SEQ ID NO: 87); GFDPEDGETIYAQKFQG (SEQ ID NO:91),encoded by the nucleic acid sequenceGGTTTTGATCCTGAAGATGGTGAAACAATCTACGCACAGAAGTTCCAGGGC (SEQ ID NO: 88); andYSGSSGWWAFDI (SEQ ID NO:92), encoded by the nucleic acid sequenceTATTCTGGTAGTAGTGGTTGGTGGGCTTTTGATATC (SEQ ID NO: 89). The light chainCDRs of the BG11 antibody have the following sequences: QGDSLRSYYAS (SEQID NO:96), encoded by the nucleic acid sequenceCAAGGAGACAGCCTCAGAAGCTATTATGCAAGC (SEQ ID NO:93); GKNNRPS (SEQ IDNO:97), encoded by the nucleic acid sequence GGTAAAAACAACCGGCCCTCA (SEQID NO: 94); and QTWGTGIWV (SEQ ID NO:98), encoded by the nucleic acidsequence CAGACCTGGGGCACTGGCATTTGGGTG (SEQ ID NO: 95).

An exemplary huRANTES monoclonal antibody is the A9 antibody describedherein. As shown below, the A9 antibody includes a heavy chain variableregion (SEQ ID NO:100) encoded by the nucleic acid sequence shown in SEQID NO: 99, and a light chain variable region (SEQ ID NO:102) encoded bythe nucleic acid sequence shown in SEQ ID NO:101. The CDR sequences areshown in boxes.

> A9 Heavy chain variable domain nucleic acid sequence  (SEQ ID NO: 99)

> A9 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 100)

> A9 Light chain variable domain nucleic acid sequence (SEQ ID NO: 101):

> A9 Light chain variable domain amino acid sequence  (SEQ ID NO: 102)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the A9 antibody have the followingsequences: SYAMS (SEQ ID NO:106), encoded by the nucleic acid sequenceAGCTATGCCATGAGC (SEQ ID NO: 103); AISGSGGSTYYADSVKG (SEQ ID NO:107),encoded by the nucleic acid sequenceGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGC (SEQ ID NO: 104);and DLGYCTNGVCWGIDY (SEQ ID NO:108), encoded by the nucleic acidsequence GATTTAGGATATTGTACTAATGGTGTATGCTGGGGTATTGACTAC (SEQ ID NO: 105).The light chain CDRs of the A9 antibody have the following sequences:TRSSGSIADNYVQ (SEQ ID NO:112), encoded by the nucleic acid sequenceACCCGCAGCAGTGGCAGCATTGCCGACAACTATGTGCAG (SEQ ID NO:109); DDDQRLS (SEQ IDNO:113), encoded by the nucleic acid sequence GACGATGACCAAAGACTCTCT (SEQID NO: 110); and QSYDDSNDV (SEQ ID NO:114), encoded by the nucleic acidsequence CAGTCTTATGATGACTCCAATGATGTG (SEQ ID NO: 111).

An exemplary huRANTES monoclonal antibody is the E6 antibody describedherein. As shown below, the E6 antibody includes a heavy chain variableregion (SEQ ID NO:116) encoded by the nucleic acid sequence shown in SEQID NO: 115, and a light chain variable region (SEQ ID NO:118) encoded bythe nucleic acid sequence shown in SEQ ID NO: 117. The CDR sequences areshown in boxes.

> E6 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 115):

> E6 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 116):

> E6 Light chain variable domain nucleic acid sequence (SEQ ID NO: 117):

> E6 Light chain variable domain amino acid sequence  (SEQ ID NO: 118)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the E6 antibody have the followingsequences: EIAIH (SEQ ID NO:122), encoded by the nucleic acid sequenceGAAATAGCCATACAC (SEQ ID NO: 119); SFEPEDAEAIYAQRFQG (SEQ ID NO:123),encoded by the nucleic acid sequenceAGTTTTGAGCCTGAAGATGCTGAAGCAATCTACGCACAGAGGTTCCAGGGC (SEQ ID NO: 120);and DPYYASSGSNYMEV (SEQ ID NO:124), encoded by the nucleic acid sequenceGATCCCTACTATGCTAGCAGTGGTTCTAACTACATGGAGGTC (SEQ ID NO: 121). The lightchain CDRs of the E6 antibody have the following sequences:TGSGGSISSNYVQ (SEQ ID NO:128), encoded by the nucleic acid sequenceACCGGCAGCGGCGGCAGCATTTCCAGCAACTATGTCCAG (SEQ ID NO:125); EDDQRPS (SEQ IDNO:129), encoded by the nucleic acid sequence GAGGATGACCAAAGACCCTCT (SEQID NO: 126); and HSYDGNNRWV (SEQ ID NO:130), encoded by the nucleic acidsequence CACTCTTATGATGGCAACAATCGGTGGGTC (SEQ ID NO: 127).

An exemplary huRANTES monoclonal antibody is the H6 antibody describedherein. As shown below, the H6 antibody includes a heavy chain variableregion (SEQ ID NO:132) encoded by the nucleic acid sequence shown in SEQID NO: 131, and a light chain variable region (SEQ ID NO:133) encoded bythe nucleic acid sequence shown in SEQ ID NO: 132. The CDR sequences areshown in boxes.

> H6 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 131):

> H6 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 132):

> H6 Light chain variable domain nucleic acid sequence (SEQ ID NO: 133):

> H6 Light chain variable domain amino acid sequence  (SEQ ID NO: 134)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the H6 antibody have the followingsequences: KQSMH (SEQ ID NO:138), encoded by the nucleic acid sequenceAAACAATCCATGCAC (SEQ ID NO: 135); SSNPEDDETLYAKKFQG (SEQ ID NO:139),encoded by the nucleic acid sequenceAGTTCTAATCCTGAAGATGATGAAACACTCTACGCAAAGAAGTTCCAGGGC (SEQ ID NO: 136);and DSQGFYYYYGMDV (SEQ ID NO:140), encoded by the nucleic acid sequenceGACTCCCAGGGTTTTTACTATTACTACGGTATGGACGTC (SEQ ID NO: 137). The lightchain CDRs of the H6 antibody have the following sequences:TGSSSNIGADYDVH (SEQ ID NO:144), encoded by the nucleic acid sequenceACTGGGAGCAGCTCCAACATCGGGGCAGATTATGATGTACAC (SEQ ID NO:141); DNINRPS (SEQID NO:145), encoded by the nucleic acid sequence GATAACATCAATCGGCCCTCA(SEQ ID NO: 142); and QSYDSSLSGVL (SEQ ID NO:146), encoded by thenucleic acid sequence CAGTCCTATGACAGCAGCCTGAGTGGTGTGCTA (SEQ ID NO:143).

An exemplary huRANTES monoclonal antibody is the G2 antibody describedherein. As shown below, the G2 antibody includes a heavy chain variableregion (SEQ ID NO:148) encoded by the nucleic acid sequence shown in SEQID NO: 147, and a light chain variable region (SEQ ID NO:150) encoded bythe nucleic acid sequence shown in SEQ ID NO: 149. The CDR sequences areshown in boxes.

> G2 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 147):

> G2 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 148):

> G2 Light chain variable domain nucleic acid sequence (SEQ ID NO: 149):

> G2 Light chain variable domain amino acid sequence  (SEQ ID NO: 150)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the G2 antibody have the followingsequences: ELSIH (SEQ ID NO:154), encoded by the nucleic acid sequenceGAATTATCCATTCAC (SEQ ID NO: 151); GFDPEDGETIYAQNFQG (SEQ ID NO:155),encoded by the nucleic acid sequenceGGTTTTGATCCTGAAGATGGTGAAACAATCTACGCACAGAATTTCCAGGGC (SEQ ID NO: 152);and DLTGSRDS (SEQ ID NO:156), encoded by the nucleic acid sequenceGATCTAACTGGAAGTAGGGACTCC (SEQ ID NO: 153). The light chain CDRs of theG2 antibody have the following sequences: TGSRSDIGYYNYVS (SEQ IDNO:160), encoded by the nucleic acid sequenceACTGGAAGCAGGAGTGACATTGGTTACTATAACTATGTCTCC (SEQ ID NO:157); DVTERPS (SEQID NO:161), encoded by the nucleic acid sequence GATGTCACTGAGCGACCCTCA(SEQ ID NO: 158); and SSFSSGDTFVV (SEQ ID NO:162), encoded by thenucleic acid sequence AGCTCATTTTCAAGTGGCGACACCTTCGTGGTT (SEQ ID NO:159).

An exemplary huRANTES monoclonal antibody is the E10 antibody describedherein. As shown below, the E10 antibody includes a heavy chain variableregion (SEQ ID NO:164) encoded by the nucleic acid sequence shown in SEQID NO: 163, and a light chain variable region (SEQ ID NO:166) encoded bythe nucleic acid sequence shown in SEQ ID NO: 165. The CDR sequences areshown in boxes.

> E10 Heavy chain variable domain nucleic acid sequence(SEQ ID NO: 163):

> E10 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 164):

> E10 Light chain variable domain nucleic acid sequence (SEQ ID NO: 165):

> E10 Light chain variable domain amino acid sequence  (SEQ ID NO: 166)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the E10 antibody have the followingsequences: SYAMH (SEQ ID NO:28), encoded by the nucleic acid sequenceAGCTATGCTATGCAC (SEQ ID NO: 25); VISYDGSNKYYADSVKG (SEQ ID NO:29),encoded by the nucleic acid sequenceGTTATATCATATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGC (SEQ ID NO: 26); andETFPHYYYYYMDV (SEQ ID NO:30), encoded by the nucleic acid sequenceGAAACTTTCCCCCACTACTACTACTACTACATGGACGTC (SEQ ID NO: 27). The light chainCDRs of the E10 antibody have the following sequences: GGGNFDDEGVH (SEQID NO:176), encoded by the nucleic acid sequenceGGGGGAGGCAACTTTGACGATGAAGGTGTTCAC (SEQ ID NO:173); DDTGRPS (SEQ IDNO:177), encoded by the nucleic acid sequence GATGATACCGGCCGGCCCTCA (SEQID NO: 174); and QAWDSSNDHPV (SEQ ID NO:178), encoded by the nucleicacid sequence CAGGCGTGGGATAGTAGTAATGATCATCCCGTG (SEQ ID NO: 175).

An exemplary huRANTES monoclonal antibody is the C10 antibody describedherein. As shown below, the C10 antibody includes a heavy chain variableregion (SEQ ID NO:180) encoded by the nucleic acid sequence shown in SEQID NO: 179, and a light chain variable region (SEQ ID NO:182) encoded bythe nucleic acid sequence shown in SEQ ID NO: 181. The CDR sequences areshown in boxes.

> C10 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 179):

> C10 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 180):

> C10 Light chain variable domain nucleic acid sequence (SEQ ID NO: 181):

> C10 Light chain variable domain amino acid sequence  (SEQ ID NO: 182)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the C10 antibody have the followingsequences: SYAMS (SEQ ID NO:106), encoded by the nucleic acid sequenceAGCTATGCCATGAGC (SEQ ID NO: 103); AISGSGGSTYYADSVKG (SEQ ID NO:107),encoded by the nucleic acid sequenceGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGC (SEQ ID NO: 104);and VRGSSQYDFWSGSEFDY (SEQ ID NO:188), encoded by the nucleic acidsequence GTAAGGGGGAGTTCCCAGTACGATTTTTGGAGTGGGTCCGAGTTTGACTAC (SEQ ID NO:185). The light chain CDRs of the C10 antibody have the followingsequences: GGDNIGGQNVH (SEQ ID NO:192), encoded by the nucleic acidsequence GGGGGAGACAACATTGGAGGTCAAAATGTTCAC (SEQ ID NO:189); YDTDRPS (SEQID NO:193), encoded by the nucleic acid sequence TATGATACCGACCGGCCCTCA(SEQ ID NO: 190); and QVWDVDSDHPWV (SEQ ID NO:194), encoded by thenucleic acid sequence CAGGTGTGGGATGTTGATAGTGATCATCCTTGGGTG (SEQ ID NO:191).

An exemplary huRANTES monoclonal antibody is the 2D1 antibody describedherein. As shown below, the 2D1 antibody includes a heavy chain variableregion (SEQ ID NO:60) encoded by the nucleic acid sequence shown in SEQID NO: 59, and a light chain variable region (SEQ ID NO:196) encoded bythe nucleic acid sequence shown in SEQ ID NO: 195. The CDR sequences areshown in boxes.

> 2D1 Heavy chain variable domain nucleic acid sequence  (SEQ ID NO: 59)

> 2D1 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 60)

> 2D1 Light chain variable domain nucleic acid sequence (SEQ ID NO: 195):

> 2D1 Light chain variable domain amino acid sequence  (SEQ ID NO: 196)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the 2D1 antibody have the followingsequences: DFAMH (SEQ ID NO:44), encoded by the nucleic acid sequenceGACTTCGCCATGCAC (SEQ ID NO: 41); GYVPEDGDTIYAQKFQG (SEQ ID NO:45),encoded by the nucleic acid sequenceGGTTATGTTCCTGAAGATGGTGACACAATCTACGCGCAGAAGTTCCAGGGC (SEQ ID NO: 42); andDPLYSGSLSY (SEQ ID NO:64), encoded by the nucleic acid sequenceGATCCCCTGTATAGTGGGAGCTTATCCTAC (SEQ ID NO: 53). The light chain CDRs ofthe 2D1 antibody have the following sequences: GGNNIESKSVH (SEQ IDNO:14), encoded by the nucleic acid sequenceGGGGGAAACAACATTGAAAGTAAAAGTGTGCAC (SEQ ID NO:11); DDSDRPS (SEQ IDNO:15), encoded by the nucleic acid sequence GATGATAGCGACCGGCCCTCA (SEQID NO: 12); and QVWDSNTDHWV (SEQ ID NO:16), encoded by the nucleic acidsequence CAGGTGTGGGATAGTAATACTGATCATTGGGTG (SEQ ID NO: 197).

An exemplary huRANTES monoclonal antibody is the AS antibody describedherein. As shown below, the AS antibody includes a heavy chain variableregion (SEQ ID NO:200) encoded by the nucleic acid sequence shown in SEQID NO: 199, and a light chain variable region (SEQ ID NO:202) encoded bythe nucleic acid sequence shown in SEQ ID NO: 201. The CDR sequences areshown in boxes.

> A5 Heavy chain variable domain nucleic acid sequence  (SEQ ID NO: 199)

> A5 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 200)

> A5 Light chain variable domain nucleic acid sequence (SEQ ID NO: 201):

> A5 Light chain variable domain amino acid sequence  (SEQ ID NO: 202)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the AS antibody have the followingsequences: ELSIH (SEQ ID NO:154), encoded by the nucleic acid sequenceGAATTATCCATACAC (SEQ ID NO: 203); YIDPEDGEPIYAQKFQG (SEQ ID NO:207),encoded by the nucleic acid sequenceTATATTGATCCTGAAGATGGTGAACCAATTTACGCACAGAAGTTCCAGGGC (SEQ ID NO: 204);and VTGSTSDAFDL (SEQ ID NO:208), encoded by the nucleic acid sequenceGTCACTGGAAGTACTTCGGATGCCTTTGATCTC (SEQ ID NO: 205). The light chain CDRsof the AS antibody have the following sequences: GGANLWGLGVH (SEQ IDNO:212), encoded by the nucleic acid sequenceGGGGGAGCCAATCTTTGGGGTCTAGGTGTCCAT (SEQ ID NO:209); DNSDRAS (SEQ IDNO:213), encoded by the nucleic acid sequence GATAATAGCGACCGGGCCTCA (SEQID NO: 210); and QVWDSSSDHWV (SEQ ID NO:214), encoded by the nucleicacid sequence CAGGTGTGGGATAGTAGTAGTGATCACTGGGTG (SEQ ID NO: 211).

An exemplary huRANTES monoclonal antibody is the H11 antibody describedherein. As shown below, the H11 antibody includes a heavy chain variableregion (SEQ ID NO:216) encoded by the nucleic acid sequence shown in SEQID NO: 215, and a light chain variable region (SEQ ID NO:218) encoded bythe nucleic acid sequence shown in SEQ ID NO: 217. The CDR sequences areshown in boxes.

> H11 Heavy chain variable domain nucleic acid sequence (SEQ ID NO: 215)

> H11 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 216)

> H11 Light chain variable domain nucleic acid sequence (SEQ ID NO: 217):

> H11 Light chain variable domain amino acid sequence  (SEQ ID NO: 218)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the H11 antibody have the followingsequences: NYALS (SEQ ID NO:222), encoded by the nucleic acid sequenceAACTATGCTCTCAGC (SEQ ID NO: 219); GFIPLVDTTNYAQRFQG (SEQ ID NO:223),encoded by the nucleic acid sequenceGGGTTCATCCCTCTCGTCGATACTACGAACTACGCACAGAGGTTTCAGGGC (SEQ ID NO: 220);and EQVAVGPGPTSDRGPDGLDV (SEQ ID NO:224), encoded by the nucleic acidsequence GAGCAGGTGGCGGTGGGACCTGGACCCACCTCAGACCGGGGGCCCGATGGTCTTGATGTC(SEQ ID NO: 221). The light chain CDRs of the H11 antibody have thefollowing sequences: TGSNSNLGADYDVH (SEQ ID NO:228), encoded by thenucleic acid sequence ACTGGGAGCAACTCCAACCTCGGGGCGGATTATGATGTACAC (SEQ IDNO:225); DNNIRPS (SEQ ID NO:229), encoded by the nucleic acid sequenceGATAACAACATTCGTCCCTCA (SEQ ID NO: 226); and QSYDTGLTSSDVI (SEQ IDNO:230), encoded by the nucleic acid sequenceCAGTCGTATGACACCGGCCTGACTTCTTCGGATGTGATA (SEQ ID NO: 227).

An exemplary huRANTES monoclonal antibody is the D1 antibody describedherein. As shown below, the D1 antibody includes a heavy chain variableregion (SEQ ID NO:232) encoded by the nucleic acid sequence shown in SEQID NO: 231, and a light chain variable region (SEQ ID NO:234) encoded bythe nucleic acid sequence shown in SEQ ID NO: 233. The CDR sequences areshown in boxes.

> D1 Heavy chain variable domain nucleic acid sequence  (SEQ ID NO: 231)

> D1 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 232)

> D1 Light chain variable domain nucleic acid sequence (SEQ ID NO: 233):

> D1 Light chain variable domain amino acid sequence  (SEQ ID NO: 234)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the Dl antibody have the followingsequences: DYYIH (SEQ ID NO:74), encoded by the nucleic acid sequenceGACTACTACATACAC (SEQ ID NO: 71); LVDSEEDGETLFAETFRG(SEQ ID NO:239),encoded by the nucleic acid sequenceCTTGTTGATTCTGAAGAAGATGGTGAAACATTATTCGCAGAGACTTTCAGGGGC (SEQ ID NO: 236);and EYGEYGFFQS (SEQ ID NO:240), encoded by the nucleic acid sequenceGAATATGGTGAATATGGGTTCTTCCAATCG (SEQ ID NO: 237). The light chain CDRs ofthe D1 antibody have the following sequences: TGSSSNIGADYDVN (SEQ IDNO:244), encoded by the nucleic acid sequenceACTGGGAGCAGCTCCAACATCGGGGCAGATTATGATGTAAAC (SEQ ID NO:241); GDINRPS (SEQID NO:245), encoded by the nucleic acid sequence GGTGACATCAATCGGCCCTCA(SEQ ID NO: 242); and QSFDNSLSGSVI (SEQ ID NO:246), encoded by thenucleic acid sequence CAGTCGTTTGACAACAGCCTGAGTGGGTCTGTGATT (SEQ ID NO:243).

An exemplary huRANTES monoclonal antibody is the E7 antibody describedherein. As shown below, the E7 antibody includes a heavy chain variableregion (SEQ ID NO:248) encoded by the nucleic acid sequence shown in SEQID NO: 247, and a light chain variable region (SEQ ID NO:250) encoded bythe nucleic acid sequence shown in SEQ ID NO: 249. The CDR sequences areshown in boxes.

> E7 Heavy chain variable domain nucleic acid sequence  (SEQ ID NO: 247)

> E7 Heavy chain variable domain amino acid sequence  (SEQ ID NO: 248)

> E7 Light chain variable domain nucleic acid sequence (SEQ ID NO: 249):

> E7 Light chain variable domain amino acid sequence  (SEQ ID NO: 250)

The amino acids encompassing the complementarity determining regions(CDR) are as defined by Chothia et al. and E. A. Kabat et al. (SeeChothia, C, et al., Nature 342:877-883 (1989); Kabat, E A, et al.,Sequences of Protein of immunological interest, Fifth Edition, USDepartment of Health and Human Services, US Government Printing Office(1991)). The heavy chain CDRs of the E7 antibody have the followingsequences: NYALS (SEQ ID NO:222), encoded by the nucleic acid sequenceAACTACGCTCTGAGC (SEQ ID NO: 251); AVIPLVETTSYAQRFQG (SEQ ID NO:255),encoded by the nucleic acid sequenceGCGGTCATCCCTCTCGTCGAGACTACGAGCTACGCACAGAGGTTCCAGGGC (SEQ ID NO: 252);and EQVAVGPGPTSNRGPDGLDV (SEQ ID NO:169), encoded by the nucleic acidsequence GAGCAGGTGGCGGTGGGACCTGGACCCACTTCAAATCGGGGGCCCGATGGCCTAGATGTC(SEQ ID NO: 253). The light chain CDRs of the E7 antibody have thefollowing sequences: TGSSSNIGDGYDVH (SEQ ID NO:190), encoded by thenucleic acid sequence ACTGGGAGCAGCTCCAACATCGGGGACGGTTATGATGTACAC (SEQ IDNO:183); GNSNRPS (SEQ ID NO:191), encoded by the nucleic acid sequenceGGTAACAGTAATCGGCCCTCA (SEQ ID NO: 184); and GTWDDILNGWV (SEQ ID NO:235),encoded by the nucleic acid sequence GGAACATGGGATGACATCCTGAATGGTTGGGTG(SEQ ID NO: 189).

huRANTES antibodies of the invention also include antibodies thatinclude a heavy chain variable amino acid sequence that is at least 90%,92%, 95%, 97%, 98%, 99% or more identical the amino acid sequence of SEQID NO: 2, 18, 22, 38, 48, 52, 56, 60, 68, 84, 100, 116, 132, 148, 164,180, 200, 216, 232, or 248 and/or a light chain variable amino acid thatis at least 90%, 92%, 95%, 97%, 98%, 99% or more identical the aminoacid sequence of SEQ ID NO: 4, 24, 40, 62, 70, 86, 102, 118, 134, 150,166, 182, 196, 202, 218, 234, or 250.

Alternatively, the monoclonal antibody is an antibody that binds to thesame epitope as 1D9, 1E4, C8, 3E7, 4D8, 5E1, 6A8, 7B5, CG11, BG11, A9,E6, H6, G2, E10, C10, 2D1, A5, H11, D1 and/or E7.

Unless otherwise defined, scientific and technical terms used inconnection with the present invention shall have the meanings that arecommonly understood by those of ordinary skill in the art. Further,unless otherwise required by context, singular terms shall includepluralities and plural terms shall include the singular. Generally,nomenclatures utilized in connection with, and techniques of, cell andtissue culture, molecular biology, and protein and oligo- orpolynucleotide chemistry and hybridization described herein are thosewell known and commonly used in the art. Standard techniques are usedfor recombinant DNA and oligonucleotide synthesis, as well as tissueculture and transformation (e.g., electroporation, lipofection).Enzymatic reactions and purification techniques are performed accordingto manufacturer's specifications or as commonly accomplished in the artor as described herein. The foregoing techniques and procedures aregenerally performed according to conventional methods well known in theart and as described in various general and more specific referencesthat are cited and discussed throughout the present specification. Seee.g., Sambrook et al. Molecular Cloning: A Laboratory Manual (2d ed.,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)).The nomenclatures utilized in connection with, and the laboratoryprocedures and techniques of analytical chemistry, synthetic organicchemistry, and medicinal and pharmaceutical chemistry described hereinare those well known and commonly used in the art. Standard techniquesare used for chemical syntheses, chemical analyses, pharmaceuticalpreparation, formulation, delivery and treatment of patients.

As utilized in accordance with the present disclosure, the followingterms, unless otherwise indicated, shall be understood to have thefollowing meanings:

As used herein, the term “antibody” refers to immunoglobulin moleculesand immunologically active portions of immunoglobulin (Ig) molecules,i.e., molecules that contain an antigen binding site that specificallybinds (immunoreacts with) an antigen. Such antibodies include, but arenot limited to, polyclonal, monoclonal, chimeric, single chain, F_(ab),F_(ab′) and F_((ab′)2) fragments, and antibodies in an F_(ab) expressionlibrary. By “specifically bind” or “immunoreacts with” is meant that theantibody reacts with one or more antigenic determinants of the desiredantigen and does not react (i.e., bind) with other polypeptides or bindsat much lower affinity (K_(d)>10⁻⁶) with other polypeptides.

The basic antibody structural unit is known to comprise a tetramer. Eachtetramer is composed of two identical pairs of polypeptide chains, eachpair having one “light” (about 25 kDa) and one “heavy” chain (about50-70 kDa). The amino-terminal portion of each chain includes a variableregion of about 100 to 110 or more amino acids primarily responsible forantigen recognition. The carboxy-terminal portion of each chain definesa constant region primarily responsible for effector function. Humanlight chains are classified as kappa and lambda light chains. Heavychains are classified as mu, delta, gamma, alpha, or epsilon, and definethe antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.Within light and heavy chains, the variable and constant regions arejoined by a “J” region of about 12 or more amino acids, with the heavychain also including a “D” region of about 10 more amino acids. Seegenerally, Fundamental Immunology Ch. 7 (Paul, W., ea., 2nd ed. RavenPress, N.Y. (1989)). The variable regions of each light/heavy chain pairform the antibody binding site.

The term “monoclonal antibody” (MAb) or “monoclonal antibodycomposition”, as used herein, refers to a population of antibodymolecules that contain only one molecular species of antibody moleculeconsisting of a unique light chain gene product and a unique heavy chaingene product. In particular, the complementarity determining regions(CDRs) of the monoclonal antibody are identical in all the molecules ofthe population. MAbs contain an antigen binding site capable ofimmunoreacting with a particular epitope of the antigen characterized bya unique binding affinity for it.

In general, antibody molecules obtained from humans relate to any of theclasses IgG, IgM, IgA, IgE and IgD, which differ from one another by thenature of the heavy chain present in the molecule. Certain classes havesubclasses as well, such as IgG₁, IgG₂, and others. Furthermore, inhumans, the light chain may be a kappa chain or a lambda chain.

The term “antigen-binding site,” or “binding portion” refers to the partof the immunoglobulin molecule that participates in antigen binding. Theantigen binding site is formed by amino acid residues of the N-terminalvariable (“V”) regions of the heavy (“H”) and light (“L”) chains. Threehighly divergent stretches within the V regions of the heavy and lightchains, referred to as “hypervariable regions,” are interposed betweenmore conserved flanking stretches known as “framework regions,” or“FRs”. Thus, the term “FR” refers to amino acid sequences which arenaturally found between, and adjacent to, hypervariable regions inimmunoglobulins. In an antibody molecule, the three hypervariableregions of a light chain and the three hypervariable regions of a heavychain are disposed relative to each other in three dimensional space toform an antigen-binding surface. The antigen-binding surface iscomplementary to the three-dimensional surface of a bound antigen, andthe three hypervariable regions of each of the heavy and light chainsare referred to as “complementarity-determining regions,” or “CDRs.” Theassignment of amino acids to each domain is in accordance with thedefinitions of Kabat Sequences of Proteins of Immunological Interest(National Institutes of Health, Bethesda, Md. (1987 and 1991)), orChothia & Lesk J. Mol. Biol. 196:901-917 (1987), Chothia et al. Nature342:878-883 (1989).

As used herein, the term “epitope” includes any protein determinantcapable of specific binding to an immunoglobulin or fragment thereof, ora T-cell receptor. The term “epitope” includes any protein determinantcapable of specific binding to an immunoglobulin or T-cell receptor.Epitopic determinants usually consist of chemically active surfacegroupings of molecules such as amino acids or sugar side chains andusually have specific three dimensional structural characteristics, aswell as specific charge characteristics. An antibody is said tospecifically bind an antigen when the dissociation constant is ≦1 μM;e.g., ≦100 nM, preferably ≦10 nM and more preferably ≦1 nM.

As used herein, the terms “immunological binding,” and “immunologicalbinding properties” refer to the non-covalent interactions of the typewhich occur between an immunoglobulin molecule and an antigen for whichthe immunoglobulin is specific. The strength, or affinity ofimmunological binding interactions can be expressed in terms of thedissociation constant (K_(d)) of the interaction, wherein a smallerK_(d) represents a greater affinity. Immunological binding properties ofselected polypeptides are quantified using methods well known in theart. One such method entails measuring the rates of antigen-bindingsite/antigen complex formation and dissociation, wherein those ratesdepend on the concentrations of the complex partners, the affinity ofthe interaction, and geometric parameters that equally influence therate in both directions. Thus, both the “on rate constant” (K_(on)) andthe “off rate constant” (K_(off)) can be determined by calculation ofthe concentrations and the actual rates of association and dissociation.(See Nature 361:186-87 (1993)). The ratio of K_(off)/K_(on) enables thecancellation of all parameters not related to affinity, and is equal tothe dissociation constant K_(d). (See, generally, Davies et al. (1990)Annual Rev Biochem 59:439-473). An antibody of the present invention issaid to specifically bind to a RANTES epitope when the equilibriumbinding constant (K_(d)) is ≦1 μM, e.g., ≦100 nM, preferably ≦10 nM, andmore preferably ≦1 nM, as measured by assays such as radioligand bindingassays or surface plasmon resonance (SPR) or similar assays known tothose skilled in the art. For example, the huRANTES antibodies providedherein exhibit a K_(d) in the range approximately between ≦10 nM toabout 100 pM.

Those skilled in the art will recognize that it is possible todetermine, without undue experimentation, if a human monoclonal antibodyhas the same specificity as a human monoclonal antibody of the invention(e.g., monoclonal antibody D9, E4 or C8) by ascertaining whether theformer prevents the latter from binding to a RANTES antigen polypeptide.If the human monoclonal antibody being tested competes with a humanmonoclonal antibody of the invention, as shown by a decrease in bindingby the human monoclonal antibody of the invention, then the twomonoclonal antibodies bind to the same, or a closely related, epitope.Another way to determine whether a human monoclonal antibody has thespecificity of a human monoclonal antibody of the invention is topre-incubate the human monoclonal antibody of the invention with theRANTES antigen polypeptide with which it is normally reactive, and thenadd the human monoclonal antibody being tested to determine if the humanmonoclonal antibody being tested is inhibited in its ability to bind theRANTES antigen polypeptide. If the human monoclonal antibody beingtested is inhibited then, in all likelihood, it has the same, orfunctionally equivalent, epitopic specificity as the monoclonal antibodyof the invention.

Various procedures known within the art are used for the production ofthe monoclonal antibodies directed against a protein such as a RANTESprotein, or against derivatives, fragments, analogs homologs ororthologs thereof. (See, e.g., Antibodies: A Laboratory Manual, HarlowE, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y., incorporated herein by reference). Fully human antibodiesare antibody molecules in which the entire sequence of both the lightchain and the heavy chain, including the CDRs, arise from human genes.Such antibodies are termed “human antibodies”, or “fully humanantibodies” herein. Human monoclonal antibodies are prepared, forexample, using the procedures described in the Examples provided below.Human monoclonal antibodies can be also prepared by using the triomatechnique; the human B-cell hybridoma technique (see Kozbor, et al.,1983 Immunol Today 4: 72); and the EBV hybridoma technique to producehuman monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONALANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Humanmonoclonal antibodies may be utilized and may be produced by using humanhybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80:2026-2030) or by transforming human B-cells with Epstein Barr Virus invitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCERTHERAPY, Alan R. Liss, Inc., pp. 77-96).

Antibodies are purified by well-known techniques, such as affinitychromatography using protein A or protein G. Subsequently, oralternatively, the specific antigen which is the target of theimmunoglobulin sought, or an epitope thereof, may be immobilized on acolumn to purify the immune specific antibody by immunoaffinitychromatography. Purification of immunoglobulins is discussed, forexample, by D. Wilkinson (The Scientist, published by The Scientist,Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).

In some instances, it may be desirable to modify the antibody of theinvention with respect to effector function, so as to enhance, e.g., theeffectiveness of the antibody in treating immune-related diseases. Forexample, cysteine residue(s) can be introduced into the Fc region,thereby allowing interchain disulfide bond formation in this region. Thehomodimeric antibody thus generated can have improved internalizationcapability and/or increased complement-mediated cell killing andantibody-dependent cellular cytotoxicity (ADCC). (See Caron et al., J.Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922(1992)). Alternatively, an antibody can be engineered that has dual Fcregions and can thereby have enhanced complement lysis and ADCCcapabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230(1989)). In a preferred embodiment, the huRANTES antibodies of theinvention are not modified with respect to effector function.

The invention also includes F_(v), F_(ab), F_(ab′) and F_((ab′)2)huRANTES antibody fragments, single chain huRANTES antibodies,bispecific huRANTES antibodies and heteroconjugate huRANTES antibodies.

Bispecific antibodies are antibodies that have binding specificities forat least two different antigens. In the present case, one of the bindingspecificities is for RANTES. The second binding target is any otherantigen, and in some embodiments, the second binding target is anextracellular target such as a cell-surface protein or receptor orreceptor subunit.

Methods for making bispecific antibodies are known in the art.Traditionally, the recombinant production of bispecific antibodies isbased on the co-expression of two immunoglobulin heavy-chain/light-chainpairs, where the two heavy chains have different specificities (Milsteinand Cuello, Nature, 305:537-539 (1983)). Because of the randomassortment of immunoglobulin heavy and light chains, these hybridomas(quadromas) produce a potential mixture of ten different antibodymolecules, of which only one has the correct bispecific structure. Thepurification of the correct molecule is usually accomplished by affinitychromatography steps. Similar procedures are disclosed in WO 93/08829,published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659(1991).

Antibody variable domains with the desired binding specificities(antibody-antigen combining sites) can be fused to immunoglobulinconstant domain sequences. The fusion preferably is with animmunoglobulin heavy-chain constant domain, comprising at least part ofthe hinge, CH2, and CH3 regions. It is preferred to have the firstheavy-chain constant region (CH1) containing the site necessary forlight-chain binding present in at least one of the fusions. DNAsencoding the immunoglobulin heavy-chain fusions and, if desired, theimmunoglobulin light chain, are inserted into separate expressionvectors, and are co-transfected into a suitable host organism. Forfurther details of generating bispecific antibodies see, for example,Suresh et al., Methods in Enzymology, 121:210 (1986).

Other approaches for generating bispecific antibodies are described,e.g., in WO 96/27011, which is hereby incorporated by reference in itsentirety. Bispecific antibodies can be prepared as full lengthantibodies or antibody fragments (e.g. F(ab′)₂ bispecific antibodies).Techniques for generating bispecific antibodies from antibody fragmentshave been described in the literature. For example, bispecificantibodies can be prepared using chemical linkage. See e.g., Brennan etal., Science 229:81 (1985), which is hereby incorporated by reference inits entirety.

Additionally, Fab′ fragments can be directly recovered from E. coli andchemically coupled to form bispecific antibodies. See e.g., Shalaby etal., J. Exp. Med. 175:217-225 (1992), which is hereby incorporated byreference in its entirety.

Various techniques for making and isolating bispecific antibodyfragments directly from recombinant cell culture have also beendescribed. For example, bispecific antibodies have been produced usingleucine zippers. See e.g., Kostelny et al., J. Immunol. 148(5):1547-1553(1992), which is hereby incorporated by reference in its entirety. The“diabody” technology described by Hollinger et al., Proc. Natl. Acad.Sci. USA 90:6444-6448 (1993), which is hereby incorporated by referencein its entirety, has provided an alternative mechanism for makingbispecific antibody fragments. Another strategy for making bispecificantibody fragments by the use of single-chain Fv (sFv) dimers has alsobeen reported. See, Gruber et al., J. Immunol. 152:5368 (1994), which ishereby incorporated by reference in its entirety.

Antibodies with more than two valencies are contemplated. For example,trispecific antibodies can be prepared. See, Tutt et al., J. Immunol.147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, atleast one of which originates in the protein antigen of the invention.Alternatively, an anti-antigenic arm of an immunoglobulin molecule canbe combined with an arm which binds to a triggering molecule on aleukocyte such as a T-cell receptor molecule (e.g. CD2, IFNγ, CD28, orB7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32)and FcγRIII (CD16) so as to focus cellular defense mechanisms to thecell expressing the particular antigen. Bispecific antibodies can alsobe used to direct cytotoxic agents to cells which express a particularantigen. These antibodies possess an antigen-binding arm and an armwhich binds a cytotoxic agent or a radionuclide chelator, such asEOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interestbinds the protein antigen described herein and further binds tissuefactor (TF).

Heteroconjugate antibodies are also within the scope of the presentinvention. Heteroconjugate antibodies are composed of two covalentlyjoined antibodies. Such antibodies have, for example, been proposed totarget immune system cells to unwanted cells (U.S. Pat. No. 4,676,980),and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP03089). It is contemplated that the antibodies can be prepared in vitrousing known methods in synthetic protein chemistry, including thoseinvolving crosslinking agents. For example, immunotoxins can beconstructed using a disulfide exchange reaction or by forming athioether bond. Examples of suitable reagents for this purpose includeiminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, forexample, in U.S. Pat. No. 4,676,980.

The invention also pertains to immunoconjugates comprising an antibodyconjugated to a cytotoxic agent such as a toxin (e.g., an enzymaticallyactive toxin of bacterial, fungal, plant, or animal origin, or fragmentsthereof), or a radioactive isotope (i.e., a radioconjugate).

Enzymatically active toxins and fragments thereof that can be usedinclude diphtheria A chain, nonbinding active fragments of diphtheriatoxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain,abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordiiproteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII,and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonariaofficinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin,enomycin, and the tricothecenes. A variety of radionuclides areavailable for the production of radioconjugated antibodies. Examplesinclude ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, and ¹⁸⁶Re.

Conjugates of the antibody and cytotoxic agent are made using a varietyof bifunctional protein-coupling agents such asN-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane(IT), bifunctional derivatives of imidoesters (such as dimethyladipimidate HCL), active esters (such as disuccinimidyl suberate),aldehydes (such as glutareldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such asbis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin canbe prepared as described in Vitetta et al., Science 238: 1098 (1987).Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent forconjugation of radionucleotide to the antibody. (See WO94/11026).

Those of ordinary skill in the art will recognize that a large varietyof possible moieties can be coupled to the resultant antibodies or toother molecules of the invention. (See, for example, “ConjugateVaccines”, Contributions to Microbiology and Immunology, J. M. Cruse andR. E. Lewis, Jr (eds), Carger Press, New York, (1989), the entirecontents of which are incorporated herein by reference).

Coupling is accomplished by any chemical reaction that will bind the twomolecules so long as the antibody and the other moiety retain theirrespective activities. This linkage can include many chemicalmechanisms, for instance covalent binding, affinity binding,intercalation, coordinate binding and complexation. The preferredbinding is, however, covalent binding. Covalent binding is achievedeither by direct condensation of existing side chains or by theincorporation of external bridging molecules. Many bivalent orpolyvalent linking agents are useful in coupling protein molecules, suchas the antibodies of the present invention, to other molecules. Forexample, representative coupling agents can include organic compoundssuch as thioesters, carbodiimides, succinimide esters, diisocyanates,glutaraldehyde, diazobenzenes and hexamethylene diamines. This listingis not intended to be exhaustive of the various classes of couplingagents known in the art but, rather, is exemplary of the more commoncoupling agents. (See Killen and Lindstrom, Jour. Immun. 133:1335-2549(1984); Jansen et al., Immunological Reviews 62:185-216 (1982); andVitetta et al., Science 238:1098 (1987). Preferred linkers are describedin the literature. (See, for example, Ramakrishnan, S. et al., CancerRes. 44:201-208 (1984) describing use of MBS(M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also, U.S. Pat. No.5,030,719, describing use of halogenated acetyl hydrazide derivativecoupled to an antibody by way of an oligopeptide linker. Particularlypreferred linkers include: (i) EDC (1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride; (ii) SMPT(4-succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pridyl-dithio)-toluene(Pierce Chem. Co., Cat. (21558G); (iii) SPDP(succinimidyl-6[3-(2-pyridyldithio)propionamido]hexanoate (Pierce Chem.Co., Cat #21651G); (iv) Sulfo-LC-SPDP (sulfosuccinimidyl 6[3-(2-pyridyldithio)-propianamide]hexanoate (Pierce Chem. Co. Cat.#2165-G); and (v) sulfo-NHS(N-hydroxysulfo-succinimide: Pierce Chem.Co., Cat. #24510) conjugated to EDC.

The term “isolated polynucleotide” as used herein shall mean apolynucleotide of genomic, cDNA, or synthetic origin or some combinationthereof, which by virtue of its origin the “isolated polynucleotide” (1)is not associated with all or a portion of a polynucleotide in which the“isolated polynucleotide” is found in nature, (2) is operably linked toa polynucleotide which it is not linked to in nature, or (3) does notoccur in nature as part of a larger sequence.

The term “isolated protein” referred to herein means a protein of cDNA,recombinant RNA, or synthetic origin or some combination thereof, whichby virtue of its origin, or source of derivation, the “isolated protein”(1) is not associated with proteins found in nature, (2) is free ofother proteins from the same source, e.g., free of murine proteins, (3)is expressed by a cell from a different species, or (4) does not occurin nature.

The term “polypeptide” is used herein as a generic term to refer tonative protein, fragments, or analogs of a polypeptide sequence. Hence,native protein fragments, and analogs are species of the polypeptidegenus. Preferred polypeptides in accordance with the invention comprisethe human heavy chain immunoglobulin molecules presented herein and thehuman light chain immunoglobulin molecules presented herein, as well asantibody molecules formed by combinations comprising the heavy chainimmunoglobulin molecules with light chain immunoglobulin molecules, suchas kappa light chain immunoglobulin molecules, and vice versa, as wellas fragments and analogs thereof.

The term “naturally-occurring” as used herein as applied to an objectrefers to the fact that an object can be found in nature. For example, apolypeptide or polynucleotide sequence that is present in an organism(including viruses) that can be isolated from a source in nature andwhich has not been intentionally modified by man in the laboratory orotherwise is naturally-occurring.

The term “operably linked” as used herein refers to positions ofcomponents so described are in a relationship permitting them tofunction in their intended manner. A control sequence “operably linked”to a coding sequence is ligated in such a way that expression of thecoding sequence is achieved under conditions compatible with the controlsequences.

The term “control sequence” as used herein refers to polynucleotidesequences which are necessary to effect the expression and processing ofcoding sequences to which they are ligated. The nature of such controlsequences differs depending upon the host organism in prokaryotes, suchcontrol sequences generally include promoter, ribosomal binding site,and transcription termination sequence in eukaryotes, generally, suchcontrol sequences include promoters and transcription terminationsequence. The term “control sequences” is intended to include, at aminimum, all components whose presence is essential for expression andprocessing, and can also include additional components whose presence isadvantageous, for example, leader sequences and fusion partnersequences. The term “polynucleotide” as referred to herein means apolymeric boron of nucleotides of at least 10 bases in length, eitherribonucleotides or deoxynucleotides or a modified form of either type ofnucleotide. The term includes single and double stranded forms of DNA.

The term oligonucleotide referred to herein includes naturallyoccurring, and modified nucleotides linked together by naturallyoccurring, and non-naturally occurring oligonucleotide linkages.Oligonucleotides are a polynucleotide subset generally comprising alength of 200 bases or fewer. Preferably oligonucleotides are 10 to 60bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or20 to 40 bases in length. Oligonucleotides are usually single stranded,e.g., for probes, although oligonucleotides may be double stranded,e.g., for use in the construction of a gene mutant. Oligonucleotides ofthe invention are either sense or antisense oligonucleotides.

The term “naturally occurring nucleotides” referred to herein includesdeoxyribonucleotides and ribonucleotides. The term “modifiednucleotides” referred to herein includes nucleotides with modified orsubstituted sugar groups and the like. The term “oligonucleotidelinkages” referred to herein includes Oligonucleotides linkages such asphosphorothioate, phosphorodithioate, phosphoroselerloate,phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate,phosphoronmidate, and the like. See e.g., LaPlanche et al. Nucl. AcidsRes. 14:9081 (1986); Stec et al. J. Am. Chem. Soc. 106:6077 (1984),Stein et al. Nucl. Acids Res. 16:3209 (1988), Zon et al. Anti CancerDrug Design 6:539 (1991); Zon et al. Oligonucleotides and Analogues: APractical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford UniversityPress, Oxford England (1991)); Stec et al. U.S. Pat. No. 5,151,510;Uhlmann and Peyman Chemical Reviews 90:543 (1990). An oligonucleotidecan include a label for detection, if desired.

The term “selectively hybridize” referred to herein means to detectablyand specifically bind. Polynucleotides, oligonucleotides and fragmentsthereof in accordance with the invention selectively hybridize tonucleic acid strands under hybridization and wash conditions thatminimize appreciable amounts of detectable binding to nonspecificnucleic acids. High stringency conditions can be used to achieveselective hybridization conditions as known in the art and discussedherein. Generally, the nucleic acid sequence homology between thepolynucleotides, oligonucleotides, and fragments of the invention and anucleic acid sequence of interest will be at least 80%, and moretypically with preferably increasing homologies of at least 85%, 90%,95%, 99%, and 100%. Two amino acid sequences are homologous if there isa partial or complete identity between their sequences. For example, 85%homology means that 85% of the amino acids are identical when the twosequences are aligned for maximum matching. Gaps (in either of the twosequences being matched) are allowed in maximizing matching gap lengthsof 5 or less are preferred with 2 or less being more preferred.Alternatively and preferably, two protein sequences (or polypeptidesequences derived from them of at least 30 amino acids in length) arehomologous, as this term is used herein, if they have an alignment scoreof at more than 5 (in standard deviation units) using the program ALIGNwith the mutation data matrix and a gap penalty of 6 or greater. SeeDayhoff, M. O., in Atlas of Protein Sequence and Structure, pp. 101-110(Volume 5, National Biomedical Research Foundation (1972)) andSupplement 2 to this volume, pp. 1-10. The two sequences or partsthereof are more preferably homologous if their amino acids are greaterthan or equal to 50% identical when optimally aligned using the ALIGNprogram. The term “corresponds to” is used herein to mean that apolynucleotide sequence is homologous (i.e., is identical, not strictlyevolutionarily related) to all or a portion of a referencepolynucleotide sequence, or that a polypeptide sequence is identical toa reference polypeptide sequence. In contradistinction, the term“complementary to” is used herein to mean that the complementarysequence is homologous to all or a portion of a reference polynucleotidesequence. For illustration, the nucleotide sequence “TATAC” correspondsto a reference sequence “TATAC” and is complementary to a referencesequence “GTATA”.

The following terms are used to describe the sequence relationshipsbetween two or more polynucleotide or amino acid sequences: “referencesequence”, “comparison window”, “sequence identity”, “percentage ofsequence identity”, and “substantial identity”. A “reference sequence”is a defined sequence used as a basis for a sequence comparison areference sequence may be a subset of a larger sequence, for example, asa segment of a full-length cDNA or gene sequence given in a sequencelisting or may comprise a complete cDNA or gene sequence. Generally, areference sequence is at least 18 nucleotides or 6 amino acids inlength, frequently at least 24 nucleotides or 8 amino acids in length,and often at least 48 nucleotides or 16 amino acids in length. Since twopolynucleotides or amino acid sequences may each (1) comprise a sequence(i.e., a portion of the complete polynucleotide or amino acid sequence)that is similar between the two molecules, and (2) may further comprisea sequence that is divergent between the two polynucleotides or aminoacid sequences, sequence comparisons between two (or more) molecules aretypically performed by comparing sequences of the two molecules over a“comparison window” to identify and compare local regions of sequencesimilarity. A “comparison window”, as used herein, refers to aconceptual segment of at least 18 contiguous nucleotide positions or 6amino acids wherein a polynucleotide sequence or amino acid sequence maybe compared to a reference sequence of at least 18 contiguousnucleotides or 6 amino acid sequences and wherein the portion of thepolynucleotide sequence in the comparison window may comprise additions,deletions, substitutions, and the like (i.e., gaps) of 20 percent orless as compared to the reference sequence (which does not compriseadditions or deletions) for optimal alignment of the two sequences.Optimal alignment of sequences for aligning a comparison window may beconducted by the local homology algorithm of Smith and Waterman Adv.Appl. Math. 2:482 (1981), by the homology alignment algorithm ofNeedleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search forsimilarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (U.S.A.)85:2444 (1988), by computerized implementations of these algorithms(GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics SoftwarePackage Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison,Wis.), Geneworks, or MacVector software packages), or by inspection, andthe best alignment (i.e., resulting in the highest percentage ofhomology over the comparison window) generated by the various methods isselected.

The term “sequence identity” means that two polynucleotide or amino acidsequences are identical (i.e., on a nucleotide-by-nucleotide orresidue-by-residue basis) over the comparison window. The term“percentage of sequence identity” is calculated by comparing twooptimally aligned sequences over the window of comparison, determiningthe number of positions at which the identical nucleic acid base (e.g.,A, T, C, G, U or I) or residue occurs in both sequences to yield thenumber of matched positions, dividing the number of matched positions bythe total number of positions in the comparison window (i.e., the windowsize), and multiplying the result by 100 to yield the percentage ofsequence identity. The terms “substantial identity” as used hereindenotes a characteristic of a polynucleotide or amino acid sequence,wherein the polynucleotide or amino acid comprises a sequence that hasat least 85 percent sequence identity, preferably at least 90 to 95percent sequence identity, more usually at least 99 percent sequenceidentity as compared to a reference sequence over a comparison window ofat least 18 nucleotide (6 amino acid) positions, frequently over awindow of at least 24-48 nucleotide (8-16 amino acid) positions, whereinthe percentage of sequence identity is calculated by comparing thereference sequence to the sequence which may include deletions oradditions which total 20 percent or less of the reference sequence overthe comparison window. The reference sequence may be a subset of alarger sequence.

As used herein, the twenty conventional amino acids and theirabbreviations follow conventional usage. See Immunology—A Synthesis (2ndEdition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates,Sunderland Mass. (1991)). Stereoisomers (e.g., D-amino acids) of thetwenty conventional amino acids, unnatural amino acids such asα-,α-disubstituted amino acids, N-alkyl amino acids, lactic acid, andother unconventional amino acids may also be suitable components forpolypeptides of the present invention. Examples of unconventional aminoacids include: 4 hydroxyproline, γ-carboxyglutamate,ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine,N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine,σ-N-methylarginine, and other similar amino acids and imino acids (e.g.,4-hydroxyproline). In the polypeptide notation used herein, the lefthanddirection is the amino terminal direction and the righthand direction isthe carboxy-terminal direction, in accordance with standard usage andconvention.

Similarly, unless specified otherwise, the lefthand end ofsingle-stranded polynucleotide sequences is the 5′ end the lefthanddirection of double-stranded polynucleotide sequences is referred to asthe 5′ direction. The direction of 5′ to 3′ addition of nascent RNAtranscripts is referred to as the transcription direction sequenceregions on the DNA strand having the same sequence as the RNA and whichare 5′ to the 5′ end of the RNA transcript are referred to as “upstreamsequences”, sequence regions on the DNA strand having the same sequenceas the RNA and which are 3′ to the 3′ end of the RNA transcript arereferred to as “downstream sequences”.

As applied to polypeptides, the term “substantial identity” means thattwo peptide sequences, when optimally aligned, such as by the programsGAP or BESTFIT using default gap weights, share at least 80 percentsequence identity, preferably at least 90 percent sequence identity,more preferably at least 95 percent sequence identity, and mostpreferably at least 99 percent sequence identity.

Preferably, residue positions which are not identical differ byconservative amino acid substitutions.

Conservative amino acid substitutions refer to the interchangeability ofresidues having similar side chains. For example, a group of amino acidshaving aliphatic side chains is glycine, alanine, valine, leucine, andisoleucine; a group of amino acids having aliphatic-hydroxyl side chainsis serine and threonine; a group of amino acids having amide-containingside chains is asparagine and glutamine; a group of amino acids havingaromatic side chains is phenylalanine, tyrosine, and tryptophan; a groupof amino acids having basic side chains is lysine, arginine, andhistidine; and a group of amino acids having sulfur-containing sidechains is cysteine and methionine. Preferred conservative amino acidssubstitution groups are: valine-leucine-isoleucine,phenylalanine-tyrosine, lysine-arginine, alanine valine,glutamic-aspartic, and asparagine-glutamine.

As discussed herein, minor variations in the amino acid sequences ofantibodies or immunoglobulin molecules are contemplated as beingencompassed by the present invention, providing that the variations inthe amino acid sequence maintain at least 75%, more preferably at least80%, 90%, 95%, and most preferably 99%. In particular, conservativeamino acid replacements are contemplated. Conservative replacements arethose that take place within a family of amino acids that are related intheir side chains. Genetically encoded amino acids are generally dividedinto families: (1) acidic amino acids are aspartate, glutamate; (2)basic amino acids are lysine, arginine, histidine; (3) non-polar aminoacids are alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan, and (4) uncharged polar amino acids are glycine,asparagine, glutamine, cysteine, serine, threonine, tyrosine. Thehydrophilic amino acids include arginine, asparagine, aspartate,glutamine, glutamate, histidine, lysine, serine, and threonine. Thehydrophobic amino acids include alanine, cysteine, isoleucine, leucine,methionine, phenylalanine, proline, tryptophan, tyrosine and valine.Other families of amino acids include (i) serine and threonine, whichare the aliphatic-hydroxy family; (ii) asparagine and glutamine, whichare the amide containing family; (iii) alanine, valine, leucine andisoleucine, which are the aliphatic family; and (iv) phenylalanine,tryptophan, and tyrosine, which are the aromatic family. For example, itis reasonable to expect that an isolated replacement of a leucine withan isoleucine or valine, an aspartate with a glutamate, a threonine witha serine, or a similar replacement of an amino acid with a structurallyrelated amino acid will not have a major effect on the binding orproperties of the resulting molecule, especially if the replacement doesnot involve an amino acid within a framework site. Whether an amino acidchange results in a functional peptide can readily be determined byassaying the specific activity of the polypeptide derivative. Assays aredescribed in detail herein. Fragments or analogs of antibodies orimmunoglobulin molecules can be readily prepared by those of ordinaryskill in the art. Preferred amino- and carboxy-termini of fragments oranalogs occur near boundaries of functional domains. Structural andfunctional domains can be identified by comparison of the nucleotideand/or amino acid sequence data to public or proprietary sequencedatabases. Preferably, computerized comparison methods are used toidentify sequence motifs or predicted protein conformation domains thatoccur in other proteins of known structure and/or function. Methods toidentify protein sequences that fold into a known three-dimensionalstructure are known. Bowie et al. Science 253:164 (1991). Thus, theforegoing examples demonstrate that those of skill in the art canrecognize sequence motifs and structural conformations that may be usedto define structural and functional domains in accordance with theinvention.

Preferred amino acid substitutions are those which: (1) reducesusceptibility to proteolysis, (2) reduce susceptibility to oxidation,(3) alter binding affinity for forming protein complexes, (4) alterbinding affinities, and (4) confer or modify other physicochemical orfunctional properties of such analogs. Analogs can include variousmuteins of a sequence other than the naturally-occurring peptidesequence. For example, single or multiple amino acid substitutions(preferably conservative amino acid substitutions) may be made in thenaturally-occurring sequence (preferably in the portion of thepolypeptide outside the domain(s) forming intermolecular contacts. Aconservative amino acid substitution should not substantially change thestructural characteristics of the parent sequence (e.g., a replacementamino acid should not tend to break a helix that occurs in the parentsequence, or disrupt other types of secondary structure thatcharacterizes the parent sequence). Examples of art-recognizedpolypeptide secondary and tertiary structures are described in Proteins,Structures and Molecular Principles (Creighton, Ed., W. H. Freeman andCompany, New York (1984)); Introduction to Protein Structure (C. Brandenand J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); andThornton et at. Nature 354:105 (1991).

The term “polypeptide fragment” as used herein refers to a polypeptidethat has an amino terminal and/or carboxy-terminal deletion, but wherethe remaining amino acid sequence is identical to the correspondingpositions in the naturally-occurring sequence deduced, for example, froma full length cDNA sequence. Fragments typically are at least 5, 6, 8 or10 amino acids long, preferably at least 14 amino acids long' morepreferably at least 20 amino acids long, usually at least 50 amino acidslong, and even more preferably at least 70 amino acids long. The term“analog” as used herein refers to polypeptides which are comprised of asegment of at least 25 amino acids that has substantial identity to aportion of a deduced amino acid sequence and which has at least one ofthe following properties: (1) specific binding to RANTES, under suitablebinding conditions or (2) ability to block appropriate RANTES binding.Typically, polypeptide analogs comprise a conservative amino acidsubstitution (or addition or deletion) with respect to thenaturally-occurring sequence. Analogs typically are at least 20 aminoacids long, preferably at least 50 amino acids long or longer, and canoften be as long as a full-length naturally-occurring polypeptide.

Peptide analogs are commonly used in the pharmaceutical industry asnon-peptide drugs with properties analogous to those of the templatepeptide. These types of non-peptide compound are termed “peptidemimetics” or “peptidomimetics”. Fauchere, J. Adv. Drug Res. 15:29(1986), Veber and Freidinger TIBS p. 392 (1985); and Evans et al. J.Med. Chem. 30:1229 (1987). Such compounds are often developed with theaid of computerized molecular modeling. Peptide mimetics that arestructurally similar to therapeutically useful peptides may be used toproduce an equivalent therapeutic or prophylactic effect. Generally,peptidomimetics are structurally similar to a paradigm polypeptide(i.e., a polypeptide that has a biochemical property or pharmacologicalactivity), such as human antibody, but have one or more peptide linkagesoptionally replaced by a linkage selected from the group consisting of:—CH₂NH—, —CH₂S—, —CH₂—CH₂—, —CH═CH-(cis and trans), —COCH₂—, CH(OH)CH₂—,and —CH₂SO—, by methods well known in the art. Systematic substitutionof one or more amino acids of a consensus sequence with a D-amino acidof the same type (e.g., D-lysine in place of L-lysine) may be used togenerate more stable peptides. In addition, constrained peptidescomprising a consensus sequence or a substantially identical consensussequence variation may be generated by methods known in the art (Rizoand Gierasch Ann. Rev. Biochem. 61:387 (1992)); for example, by addinginternal cysteine residues capable of forming intramolecular disulfidebridges which cyclize the peptide.

The term “agent” is used herein to denote a chemical compound, a mixtureof chemical compounds, a biological macromolecule, or an extract madefrom biological materials.

As used herein, the terms “label” or “labeled” refers to incorporationof a detectable marker, e.g., by incorporation of a radiolabeled aminoacid or attachment to a polypeptide of biotinyl moieties that can bedetected by marked avidin (e.g., streptavidin containing a fluorescentmarker or enzymatic activity that can be detected by optical orcalorimetric methods). In certain situations, the label or marker canalso be therapeutic. Various methods of labeling polypeptides andglycoproteins are known in the art and may be used. Examples of labelsfor polypeptides include, but are not limited to, the following:radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc,¹¹¹In, ¹²⁵I, ¹³¹I) fluorescent labels (e.g., FITC, rhodamine, lanthanidephosphors), enzymatic labels (e.g., horseradish peroxidase,p-galactosidase, luciferase, alkaline phosphatase), chemiluminescent,biotinyl groups, predetermined polypeptide epitopes recognized by asecondary reporter (e.g., leucine zipper pair sequences, binding sitesfor secondary antibodies, metal binding domains, epitope tags). In someembodiments, labels are attached by spacer arms of various lengths toreduce potential steric hindrance. The term “pharmaceutical agent ordrug” as used herein refers to a chemical compound or compositioncapable of inducing a desired therapeutic effect when properlyadministered to a patient.

Other chemistry terms herein are used according to conventional usage inthe art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms(Parker, S., Ed., McGraw-Hill, San Francisco (1985)).

As used herein, “substantially pure” means an object species is thepredominant species present (i.e., on a molar basis it is more abundantthan any other individual species in the composition), and preferably asubstantially purified fraction is a composition wherein the objectspecies comprises at least about 50 percent (on a molar basis) of allmacromolecular species present.

Generally, a substantially pure composition will comprise more thanabout 80 percent of all macromolecular species present in thecomposition, more preferably more than about 85%, 90%, 95%, and 99%.Most preferably, the object species is purified to essential homogeneity(contaminant species cannot be detected in the composition byconventional detection methods) wherein the composition consistsessentially of a single macromolecular species.

The term patient includes human and veterinary subjects. The termsubject includes humans and other mammals.

Human Antibodies and Humanization of Antibodies

A huRANTES antibody is generated, for example, using the proceduresdescribed in the Examples provided below.

In other, alternative methods, a huRANTES antibody is developed, forexample, using phage-display methods using antibodies containing onlyhuman sequences. Such approaches are well-known in the art, e.g., inWO92/01047 and U.S. Pat. No. 6,521,404, which are hereby incorporated byreference. In this approach, a combinatorial library of phage carryingrandom pairs of light and heavy chains are screened using natural orrecombinant source of RANTES or fragments thereof. In another approach,a huRANTES antibody can be produced by a process wherein at least onestep of the process includes immunizing a transgenic, non-human animalwith human RANTES protein. In this approach, some of the endogenousheavy and/or kappa light chain loci of this xenogenic non-human animalhave been disabled and are incapable of the rearrangement required togenerate genes encoding immunoglobulins in response to an antigen. Inaddition, at least one human heavy chain locus and at least one humanlight chain locus have been stably transfected into the animal. Thus, inresponse to an administered antigen, the human loci rearrange to providegenes encoding human variable regions immunospecific for the antigen.Upon immunization, therefore, the xenomouse produces B-cells thatsecrete fully human immunoglobulins.

A variety of techniques are well-known in the art for producingxenogenic non-human animals. For example, see U.S. Pat. Nos. 6,075,181and 6,150,584, which is hereby incorporated by reference in itsentirety. This general strategy was demonstrated in connection withgeneration of the first XenoMouse™ strains as published in 1994. SeeGreen et al. Nature Genetics 7:13-21 (1994), which is herebyincorporated by reference in its entirety. See also, U.S. Pat. Nos.6,162,963, 6,150,584, 6, 114,598, 6,075,181, and 5,939,598 and JapanesePatent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2 and EuropeanPatent No., EP 0 463 151 B1 and International Patent Applications No. WO94/02602, WO 96/34096, WO 98/24893, WO 00/76310 and related familymembers.

In an alternative approach, others have utilized a “minilocus” approachin which an exogenous Ig locus is mimicked through the inclusion ofpieces (individual genes) from the Ig locus. Thus, one or more VH genes,one or more D_(H) genes, one or more J_(H) genes, a mu constant region,and a second constant region (preferably a gamma constant region) areformed into a construct for insertion into an animal. See e.g., U.S.Pat. Nos. 5,545,806; 5,545,807; 5,591,669; 5,612,205; 5,625,825;5,625,126; 5,633,425; 5,643,763; 5,661,016; 5,721,367; 5,770,429;5,789,215; 5,789,650; 5,814,318; 5,877; 397; 5,874,299; 6,023,010; and6,255,458; and European Patent No. 0 546 073 B1; and InternationalPatent Application Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO97/13852, and WO 98/24884 and related family members.

Generation of human antibodies from mice in which, through microcellfusion, large pieces of chromosomes, or entire chromosomes, have beenintroduced, has also been demonstrated. See European Patent ApplicationNos. 773 288 and 843 961.

Human anti-mouse antibody (HAMA) responses have led the industry toprepare chimeric or otherwise humanized antibodies. While chimericantibodies have a human constant region and a immune variable region, itis expected that certain human anti-chimeric antibody (HACA) responseswill be observed, particularly in chronic or multi-dose utilizations ofthe antibody. Thus, it would be desirable to provide fully humanantibodies against RANTES in order to vitiate or otherwise mitigateconcerns and/or effects of HAMA or HACA response.

The production of antibodies with reduced immunogenicity is alsoaccomplished via humanization, chimerization and display techniquesusing appropriate libraries. It will be appreciated that murineantibodies or antibodies from other species can be humanized orprimatized using techniques well known in the art. See e.g., Winter andHarris Immunol Today 14:43 46 (1993) and Wright et al. Crit, Reviews inImmunol. 12125-168 (1992). The antibody of interest may be engineered byrecombinant DNA techniques to substitute the CH1, CH2, CH3, hingedomains, and/or the framework domain with the corresponding humansequence (See WO 92102190 and U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,761, 5,693,792, 5,714,350, and 5,777,085). Also, the use of 1g cDNAfor construction of chimeric immunoglobulin genes is known in the art(Liu et al. P.N.A.S. 84:3439 (1987) and J. Immunol. 139:3521 (1987)).mRNA is isolated from a hybridoma or other cell producing the antibodyand used to produce cDNA. The cDNA of interest may be amplified by thepolymerase chain reaction using specific primers (U.S. Pat. Nos.4,683,195 and 4,683,202). Alternatively, a library is made and screenedto isolate the sequence of interest. The DNA sequence encoding thevariable region of the antibody is then fused to human constant regionsequences. The sequences of human constant regions genes may be found inKabat et al. (1991) Sequences of Proteins of immunological Interest,N.I.H. publication no. 91-3242. Human C region genes are readilyavailable from known clones. The choice of isotype will be guided by thedesired effecter functions, such as complement fixation, or activity inantibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1,IgG3 and IgG4. Either of the human light chain constant regions, kappaor lambda, may be used. The chimeric, humanized antibody is thenexpressed by conventional methods.

Antibody fragments, such as Fv, F(ab′)₂ and Fab may be prepared bycleavage of the intact protein, e.g., by protease or chemical cleavage.Alternatively, a truncated gene is designed. For example, a chimericgene encoding a portion of the F(ab′)₂ fragment would include DNAsequences encoding the CH1 domain and hinge region of the H chain,followed by a translational stop codon to yield the truncated molecule.

Consensus sequences of H and L J regions may be used to designoligonucleotides for use as primers to introduce useful restrictionsites into the J region for subsequent linkage of V region segments tohuman C region segments. C region cDNA can be modified by site directedmutagenesis to place a restriction site at the analogous position in thehuman sequence.

Expression vectors include plasmids, retroviruses, YACs, EBV derivedepisomes, and the like. A convenient vector is one that encodes afunctionally complete human CH or CL immunoglobulin sequence, withappropriate restriction sites engineered so that any VH or VL sequencecan be easily inserted and expressed. In such vectors, splicing usuallyoccurs between the splice donor site in the inserted J region and thesplice acceptor site preceding the human C region, and also at thesplice regions that occur within the human CH exons. Polyadenylation andtranscription termination occur at native chromosomal sites downstreamof the coding regions. The resulting chimeric antibody may be joined toany strong promoter, including retroviral LTRs, e.g., SV-40 earlypromoter, (Okayama et al. Mol. Cell. Bio. 3:280 (1983)), Rous sarcomavirus LTR (Gorman et al. P.N.A.S. 79:6777 (1982)), and moloney murineleukemia virus LTR (Grosschedl et al. Cell 41:885 (1985)). Also, as willbe appreciated, native Ig promoters and the like may be used.

Further, human antibodies or antibodies from other species can begenerated through display type technologies, including, withoutlimitation, phage display, retroviral display, ribosomal display, andother techniques, using techniques well known in the art and theresulting molecules can be subjected to additional maturation, such asaffinity maturation, as such techniques are well known in the art.Wright et al. Crit, Reviews in Immunol. 12125-168 (1992), Hanes andPlückthun PNAS USA 94:4937-4942 (1997) (ribosomal display), Parmley andSmith Gene 73:305-318 (1988) (phage display), Scott, TIBS, vol.17:241-245 (1992), Cwirla et al. PNAS USA 87:6378-6382 (1990), Russel etal. Nucl. Acids Research 21:1081-1085 (1993), Hoganboom et al. Immunol.Reviews 130:43-68 (1992), Chiswell and McCafferty TIBTECH; 10:80-8A(1992), and U.S. Pat. No. 5,733,743. If display technologies areutilized to produce antibodies that are not human, such antibodies canbe humanized as described above.

Using these techniques, antibodies can be generated to RANTES expressingcells, RANTES itself, forms of RANTES, epitopes or peptides thereof, andexpression libraries thereto (See e.g., U.S. Pat. No. 5,703,057) whichcan thereafter be screened as described above for the activitiesdescribed above.

Design and Generation of Other Therapeutics

In accordance with the present invention and based on the activity ofthe antibodies that are produced and characterized herein with respectto RANTES, the design of other therapeutic modalities beyond antibodymoieties is facilitated. Such modalities include, without limitation,advanced antibody therapeutics, such as bispecific antibodies,immunotoxins, and radiolabeled therapeutics, generation of peptidetherapeutics, gene therapies, particularly intrabodies, antisensetherapeutics, and small molecules.

For example, in connection with bispecific antibodies, bispecificantibodies can be generated that comprise (i) two antibodies one with aspecificity to RANTES and another to a second molecule that areconjugated together, (ii) a single antibody that has one chain specificto RANTES and a second chain specific to a second molecule, or (iii) asingle chain antibody that has specificity to RANTES and a secondmolecule. Such bispecific antibodies are generated using techniques thatare well known for example, in connection with (i) and (ii) See e.g.,Fanger et al. Immunol Methods 4:72-81 (1994) and Wright et al. Crit,Reviews in Immunol. 12125-168 (1992), and in connection with (iii) Seee.g., Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992).

In connection with immunotoxins, antibodies can be modified to act asimmunotoxins utilizing techniques that are well known in the art. Seee.g., Vitetta Immunol Today 14:252 (1993). See also U.S. Pat. No.5,194,594. In connection with the preparation of radiolabeledantibodies, such modified antibodies can also be readily preparedutilizing techniques that are well known in the art. See e.g., Junghanset al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition,Chafner and Longo, eds., Lippincott Raven (1996)). See also U.S. Pat.Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), U.S. Pat.Nos. 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeledmolecules would be likely to kill cells expressing RANTES.

In connection with the generation of therapeutic peptides, through theutilization of structural information related to RANTES and antibodiesthereto, such as the antibodies of the invention or screening of peptidelibraries, therapeutic peptides can be generated that are directedagainst RANTES. Design and screening of peptide therapeutics isdiscussed in connection with Houghten et al. Biotechniques 13:412-421(1992), Houghten PNAS USA 82:5131-5135 (1985), Pinalla et al.Biotechniques 13:901-905 (1992), Blake and Litzi-Davis BioConjugateChem. 3:510-513 (1992). Immunotoxins and radiolabeled molecules can alsobe prepared, and in a similar manner, in connection with peptidicmoieties as discussed above in connection with antibodies. Assuming thatthe RANTES molecule (or a form, such as a splice variant or alternateform) is functionally active in a disease process, it will also bepossible to design gene and antisense therapeutics thereto throughconventional techniques. Such modalities can be utilized for modulatingthe function of RANTES. In connection therewith the antibodies of thepresent invention facilitate design and use of functional assays relatedthereto. A design and strategy for antisense therapeutics is discussedin detail in International Patent Application No. WO 94/29444. Designand strategies for gene therapy are well known. However, in particular,the use of gene therapeutic techniques involving intrabodies could proveto be particularly advantageous. See e.g., Chen et al. Human GeneTherapy 5:595-601 (1994) and Marasco Gene Therapy 4:11-15 (1997).General design of and considerations related to gene therapeutics isalso discussed in International Patent Application No. WO 97/38137.

Knowledge gleaned from the structure of the RANTES molecule and itsinteractions with other molecules in accordance with the presentinvention, such as the antibodies of the invention, and others can beutilized to rationally design additional therapeutic modalities. In thisregard, rational drug design techniques such as X-ray crystallography,computer-aided (or assisted) molecular modeling (CAMM), quantitative orqualitative structure-activity relationship (QSAR), and similartechnologies can be utilized to focus drug discovery efforts. Rationaldesign allows prediction of protein or synthetic structures which caninteract with the molecule or specific forms thereof which can be usedto modify or modulate the activity of RANTES. Such structures can besynthesized chemically or expressed in biological systems. This approachhas been reviewed in Capsey et al. Genetically Engineered HumanTherapeutic Drugs (Stockton Press, NY (1988)). Further, combinatoriallibraries can be designed and synthesized and used in screeningprograms, such as high throughput screening efforts.

Therapeutic Administration and Formulations

It will be appreciated that administration of therapeutic entities inaccordance with the invention will be administered with suitablecarriers, excipients, and other agents that are incorporated intoformulations to provide improved transfer, delivery, tolerance, and thelike. A multitude of appropriate formulations can be found in theformulary known to all pharmaceutical chemists: Remington'sPharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, Pa.(1975)), particularly Chapter 87 by Blaug, Seymour, therein. Theseformulations include, for example, powders, pastes, ointments, jellies,waxes, oils, lipids, lipid (cationic or anionic) containing vesicles(such as Lipofectin™), DNA conjugates, anhydrous absorption pastes,oil-in-water and water-in-oil emulsions, emulsions carbowax(polyethylene glycols of various molecular weights), semi-solid gels,and semi-solid mixtures containing carbowax. Any of the foregoingmixtures may be appropriate in treatments and therapies in accordancewith the present invention, provided that the active ingredient in theformulation is not inactivated by the formulation and the formulation isphysiologically compatible and tolerable with the route ofadministration. See also Baldrick P. “Pharmaceutical excipientdevelopment: the need for preclinical guidance.” Regul. ToxicolPharmacol. 32(2):210-8 (2000), Wang W. “Lyophilization and developmentof solid protein pharmaceuticals.” Int. J. Pharm. 203(1-2):1-60 (2000),Charman W N “Lipids, lipophilic drugs, and oral drug delivery-someemerging concepts.” J Pharm Sci. 89(8):967-78 (2000), Powell et al.“Compendium of excipients for parenteral formulations” PDA J Pharm SciTechnol. 52:238-311 (1998) and the citations therein for additionalinformation related to formulations, excipients and carriers well knownto pharmaceutical chemists.

The RANTES antagonists, huRANTES antibodies and therapeutic formulationsof the invention, which include a RANTES antagonist, such as a huRANTESantibody of the invention, are used to treat or alleviate ischemia, aclinical indication associated with ischemia, reperfusion injury, asymptom associated with an immune-related disorder, such as, forexample, an autoimmune disease or an inflammatory disorder.

Autoimmune diseases include, for example, Acquired ImmunodeficiencySyndrome (AIDS, which is a viral disease with an autoimmune component),alopecia greata, ankylosing spondylitis, antiphospholipid syndrome,autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmunehepatitis, autoimmune inner ear disease (AIED), autoimmunelymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura(ATP), Behcet's disease, cardiomyopathy, celiac sprue-dermatitishepetiformis; chronic fatigue immune dysfunction syndrome (CFIDS),chronic inflammatory demyelinating polyneuropathy (CIPD), cicatricialpemphigold, cold agglutinin disease, crest syndrome, Crohn's disease,Degos' disease, dermatomyositis-juvenile, discoid lupus, essential mixedcryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease,Guillain-Barré syndrome, Hashimoto's thyroiditis, idiopathic pulmonaryfibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy,insulin-dependent diabetes mellitus, juvenile chronic arthritis (Still'sdisease), juvenile rheumatoid arthritis, Ménière's disease, mixedconnective tissue disease, multiple sclerosis, myasthenia gravis,pernacious anemia, polyarteritis nodosa, polychondritis, polyglandularsyndromes, polymyalgia rheumatica, polymyositis and dermatomyositis,primary agammaglobulinemia, primary biliary cirrhosis, psoriasis,psoriatic arthritis, Raynaud's phenomena, Reiter's syndrome, rheumaticfever, rheumatoid arthritis, sarcoidosis, scleroderma (progressivesystemic sclerosis (PSS), also known as systemic sclerosis (SS)),Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus,Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerativecolitis, uveitis, vitiligo and Wegener's granulomatosis.

Inflammatory disorders include, for example, chronic and acuteinflammatory disorders. Examples of inflammatory disorders includeAlzheimer's disease, asthma, atopic allergy, allergy, atherosclerosis,bronchial asthma, eczema, glomerulonephritis, graft vs. host disease,hemolytic anemias, osteoarthritis, sepsis, stroke, transplantation oftissue and organs, vasculitis, diabetic retinopathy and ventilatorinduced lung injury.

The huRANTES antibodies modulate an immune response in a subject, e.g.,in a human subject and transplanted organ. In one embodiment, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof is used to treat ischemia, a clinical indicationassociated with ischemia, reperfusion injury, and/or anotherimmune-related disorder in conjunction with a surgical treatment orother interventional therapy used in the art to treat a given disorder.For example, interventional therapies used in the treatment of ischemia,a clinical indication associated with ischemia, and/or reperfusioninjury include surgical intervention or angioplasty. The RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof is administered simultaneously (i.e., during) theinterventional therapy, or the RANTES antagonist, huRANTES antibody,fragment thereof or therapeutic formulation thereof is administered at adifferent time than the interventional therapy. For example, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof is administered in some embodiments after aninterventional therapy.

In one embodiment, the RANTES antagonist, huRANTES antibody, fragmentthereof or therapeutic formulation thereof used to treat ischemia, aclinical indication associated with ischemia, reperfusion injury, and/oranother immune-related disorder are administered in combination with anyof a variety of anti-cytokine agents or anti-chemokine agents. Suitableanti-cytokine or anti-chemokine reagents recognize, for example,cytokines such as interleukin 1 (IL-1), IL-2, IL-4, IL-6, IL-12, IL-13,IL-15, IL-17, IL-18, IL-20, IL-21, IL-22, IL-23, IL-27 and IL-31, and/orchemokines such as MIP1 alpha, MIP1 beta, RANTES, MCP1, RANTES, ITAC,MIG, SDF and fractalkine.

In one embodiment, the RANTES antagonist, huRANTES antibody, fragmentthereof or therapeutic formulation thereof used to treat ischemia, aclinical indication associated with ischemia, reperfusion injury, and/oranother immune-related disorder are administered in conjunction with oneor more additional agents, or a combination of additional agents. Forexample, the RANTES antagonist (e.g., huRANTES antibody) and additionalagent are formulated into a single therapeutic composition, and theRANTES antagonist and additional agent are administered simultaneously.Alternatively, the RANTES antagonist and additional agent are separatefrom each other, e.g., each is formulated into a separate therapeuticcomposition, and the RANTES antagonist and the additional agent areadministered simultaneously, or the RANTES antagonist and the additionalagent are administered at different times during a treatment regimen.For example, the RANTES antagonist (e.g., huRANTES antibody) isadministered prior to the administration of the additional agent, theRANTES antagonist is administered subsequent to the administration ofthe additional agent, or the RANTES antagonist and the additional agentare administered in an alternating fashion. As described herein, theRANTES antagonist and additional agent are administered in single dosesor in multiple doses.

For example, in the treatment of coronary artery disease, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof, is administered in conjunction with one or moreadditional agents such as cholesterol-lowering medicines, such asstatins; anticoagulants, such as heparin and/or oral anticoagulants suchas warfarin and dicumarol; aspirin, and other antiplatelet medicines;ACE (angiotensin-converting enzyme) inhibitors, such assulfhydryl-containing ACE inhibitors (e.g., Captopril),dicarboxylate-containing ACE inhibitors (e.g., Enalapril, Ramipril,Quinapril, Perindopril, Lisinopril, Benazepril); phosphonate-containingACE inhibitors (e.g., Fosinopril); beta blockers; calcium channelblockers; nitroglycerin; long-acting nitrates; glycoprotein IIb-IIIainhibitors; and thrombolytic agents. The RANTES antagonist and theadditional agent are administered simultaneously, or RANTES antagonistand the additional agent are administered at different times during atreatment regimen.

For example, in the treatment of cerebral vascular disease, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof, is administered in conjunction with one or moreadditional agents such as cholesterol-lowering medicines, such asstatins, aspirin, and other antiplatelet medicines. The RANTESantagonist and the additional agent are administered simultaneously, orRANTES antagonist and the additional agent are administered at differenttimes during a treatment regimen.

For example, in the treatment of cardiac ischemia, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof, is administered in conjunction with one or moreadditional agents such as aspirin, and other antiplatelet medicines; ACE(angiotensin-converting enzyme) inhibitors, such assulfhydryl-containing ACE inhibitors (e.g., Captopril),dicarboxylate-containing ACE inhibitors (e.g., Enalapril, Ramipril,Quinapril, Perindopril, Lisinopril, Benazepril); phosphonate-containingACE inhibitors (e.g., Fosinopril); beta blockers; calcium channelblockers; nitroglycerin; and long-acting nitrates. The RANTES antagonistand the additional agent are administered simultaneously, or RANTESantagonist and the additional agent are administered at different timesduring a treatment regimen.

For example, in the treatment of myocardial ischemia, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof is administered in conjunction with one or moreadditional agents such as beta blockers; calcium channel blockers;nitroglycerin; and long-acting nitrates. The RANTES antagonist and theadditional agent are administered simultaneously, or RANTES antagonistand the additional agent are administered at different times during atreatment regimen.

For example, in the treatment of renal ischemia, the RANTES antagonist,huRANTES antibody, fragment thereof or therapeutic formulation thereofis administered in conjunction with one or more additional agents suchas cholesterol-lowering medicines, such as aspirin, and otherantiplatelet medicines. The RANTES antagonist and the additional agentare administered simultaneously, or RANTES antagonist and the additionalagent are administered at different times during a treatment regimen.

For example, in the treatment of peripheral vascular disease, the RANTESantagonist, huRANTES antibody, fragment thereof or therapeuticformulation thereof is administered in conjunction with one or moreadditional agents such as anticoagulants, such as heparin and/or oralanticoagulants such as warfarin and dicumarol; aspirin, and otherantiplatelet medicines; pentoxifylline; cilostazol ; and thrombolyticagents. The RANTES antagonist and the additional agent are administeredsimultaneously, or RANTES antagonist and the additional agent areadministered at different times during a treatment regimen.

For example, in the treatment of multiple sclerosis, the huRANTESantibody, or therapeutic formulation thereof, is administered inconjunction with one or more additional agents such as interferon beta1a, interferon beta 1b, glatiramer acetate, natalizumab, copaxone, andcombinations thereof. The huRANTES antibody and the additional agent areadministered simultaneously, or the huRANTES antibody and the additionalagent are administered at different times during a treatment regimen.

In the treatment of Crohn's disease, the huRANTES antibody, ortherapeutic formulation thereof, is administered in conjunction with oneor more additional agents such as an antibiotic, an aminosalicylate,Infliximab, Adalimumab, and combinations thereof. Suitable antibioticsinclude, e.g., metronidazole and/or ciprofloxacin. Suitableaminosalicylates include, for example, mesalamine and/or sulfasalazine.The huRANTES antibody and the additional agent are administeredsimultaneously, or the huRANTES antibody and the additional agent areadministered at different times during a treatment regimen.

In the treatment of ulcerative colitis, the huRANTES antibody, ortherapeutic formulation thereof, is administered in conjunction with oneor more additional agents such as 6-mercaptopurine, azathioprine,Infliximab and combinations thereof. The huRANTES antibody and theadditional agent are administered simultaneously, or the huRANTESantibody and the additional agent are administered at different timesduring a treatment regimen.

In the treatment of psoriasis, the huRANTES antibody, or therapeuticformulation thereof, is administered in conjunction with one or moreadditional agents such as alefacept, efalizumab, Adalimumab, Infliximab,cyclosporine, Methotrexate, and combinations thereof. The huRANTESantibody and the additional agent are administered simultaneously, orthe huRANTES antibody and the additional agent are administered atdifferent times during a treatment regimen.

In the treatment of atherosclerosis, the huRANTES antibody, ortherapeutic formulation thereof, is administered in conjunction with oneor more additional agents such as warfarin, a cholesterol lowering drug,and combinations thereof. Suitable cholesterol lowering drugs include,for example, statins and fibrates. The huRANTES antibody and theadditional agent are administered simultaneously, or the huRANTESantibody and the additional agent are administered at different timesduring a treatment regimen.

The huRANTES antibodies and therapeutic formulations thereof are used inmethods of treating or alleviating a symptom associated with animmune-related disorder. For example, the compositions of the inventionare used to treat or alleviate a symptom of any of the autoimmunediseases and inflammatory disorders described herein. Symptomsassociated with immune-related disorders include, for example,inflammation, fever, loss of appetite, weight loss, abdominal symptomssuch as, for example, abdominal pain, diarrhea or constipation, jointpain or aches (arthralgia), fatigue, rash, anemia, extreme sensitivityto cold (Raynaud's phenomenon), muscle weakness, muscle fatigue, changesin skin or tissue tone, shortness of breath or other abnormal breathingpatterns, chest pain or constriction of the chest muscles, abnormalheart rate (e.g., elevated or lowered), light sensitivity, blurry orotherwise abnormal vision, and reduced organ function.

The RANTES antagonists, such as a huRANTES antibody, and therapeuticformulations thereof are administered to a subject suffering fromischemia, a clinical indication associated with ischemia, reperfusioninjury, and/or an immune-related disorder, such as an autoimmune diseaseor an inflammatory disorder. A subject or organ suffering from ischemia,a clinical indication associated with ischemia, reperfusion injury, anautoimmune disease or an inflammatory disorder is identified by methodsknown in the art. For example, subjects are identified using any of avariety of clinical and/or laboratory tests such as, physicalexamination, radiologic examination and blood, urine and stool analysisto evaluate immune status. For example, patients suffering from lupusare identified, e.g., by using the anti-nuclear antibody test (ANA) todetermine if auto-antibodies to cell nuclei are present in the blood.Patients suffering from Crohn's are identified, e.g., using an uppergastrointestinal (GI) series and/or a colonoscopy to evaluate the smalland large intestines, respectively. Patients suffering from psoriasisare identified, e.g., using microscopic examination of tissue taken fromthe affected skin patch, while patients suffering from rheumatoidarthritis are identified using, e.g., blood tests and/or x-ray or otherimaging evaluation. Patients suffering from atherosclerosis areidentified, e.g., using blood tests, electrocardiograms (ECG), stresstesting, coronary angiography, ultrasound, and computed tomography (CT).

Administration of a RANTES antagonist, such as a huRANTES antibody, to apatient suffering from ischemia, a clinical indication associated withischemia, reperfusion injury, or an immune-related disorder such as anautoimmune disease or an inflammatory disorder is considered successfulif any of a variety of laboratory or clinical results is achieved. Forexample, administration of a huRANTES antibody to a patient sufferingfrom ischemia, a clinical indication associated with ischemia,reperfusion injury, an immune-related disorder such as an autoimmunedisease or an inflammatory disorder is considered successful one or moreof the symptoms associated with the disorder is alleviated, reduced,inhibited or does not progress to a further, i.e., worse, state.Administration of a huRANTES antibody to a patient suffering fromischemia, a clinical indication associated with ischemia, reperfusioninjury, an immune-related disorder such as an autoimmune disease or aninflammatory disorder is considered successful if the disorder, e.g., anautoimmune disorder, enters remission or does not progress to a further,i.e., worse, state.

Diagnostic and Prophylactic Formulations

The fully human anti-RANTES MAbs of the invention are used in diagnosticand prophylactic formulations. In one embodiment, a RANTES antagonist,such as a huRANTES MAb of the invention, is administered to patientsthat are at risk of developing ischemia, a clinical indicationassociated with ischemia, reperfusion injury, and/or one of theaforementioned autoimmune diseases. A patient's or organ'spredisposition to ischemia, a clinical indication associated withischemia, reperfusion injury, and/or one or more of the aforementionedautoimmune diseases can be determined using genotypic, serological orbiochemical markers.

In another embodiment of the invention, a RANTES antagonist, such as ahuRANTES antibody is administered to human individuals diagnosed with aclinical indication associated with ischemia, reperfusion injury, one ormore of the aforementioned autoimmune diseases. Upon diagnosis, a RANTESantagonist, such as a huRANTES antibody is administered to mitigate orreverse the effects of the clinical indication associated with ischemia,reperfusion injury, or autoimmunity.

Antibodies of the invention are also useful in the detection of RANTESin patient samples and accordingly are useful as diagnostics. Forexample, the huRANTES antibodies of the invention are used in in vitroassays, e.g., ELISA, to detect RANTES levels in a patient sample.

In one embodiment, a huRANTES antibody of the invention is immobilizedon a solid support (e.g., the well(s) of a microtiter plate). Theimmobilized antibody serves as a capture antibody for any RANTES thatmay be present in a test sample. Prior to contacting the immobilizedantibody with a patient sample, the solid support is rinsed and treatedwith a blocking agent such as milk protein or albumin to preventnonspecific adsorption of the analyte.

Subsequently the wells are treated with a test sample suspected ofcontaining the antigen, or with a solution containing a standard amountof the antigen. Such a sample is, e.g., a serum sample from a subjectsuspected of having levels of circulating antigen considered to bediagnostic of a pathology. After rinsing away the test sample orstandard, the solid support is treated with a second antibody that isdetectably labeled. The labeled second antibody serves as a detectingantibody. The level of detectable label is measured, and theconcentration of RANTES antigen in the test sample is determined bycomparison with a standard curve developed from the standard samples.

It will be appreciated that based on the results obtained using thehuRANTES antibodies of the invention in an in vitro diagnostic assay, itis possible to stage a disease (e.g., a clinical indication associatedwith ischemia, an autoimmune or inflammatory disorder) in a subjectbased on expression levels of the RANTES antigen. For a given disease,samples of blood are taken from subjects diagnosed as being at variousstages in the progression of the disease, and/or at various points inthe therapeutic treatment of the disease. Using a population of samplesthat provides statistically significant results for each stage ofprogression or therapy, a range of concentrations of the antigen thatmay be considered characteristic of each stage is designated.

All publications and patent documents cited herein are incorporatedherein by reference as if each such publication or document wasspecifically and individually indicated to be incorporated herein byreference. Citation of publications and patent documents is not intendedas an admission that any is pertinent prior art, nor does it constituteany admission as to the contents or date of the same. The inventionhaving now been described by way of written description, those of skillin the art will recognize that the invention can be practiced in avariety of embodiments and that the foregoing description and examplesbelow are for purposes of illustration and not limitation of the claimsthat follow.

EXAMPLES

The following examples, including the experiments conducted and resultsachieved are provided for illustrative purposes only and are not to beconstrued as limiting upon the present invention.

Example 1 Cloning, Expression and Purification of Human RANTES

Cloning

The gene encoding the mature protein human RANTES (GenBank Accession No.M21121) or other chemokines were cloned in an expression plasmid pET43(Novagen Madison, Wis.) by PCR amplification. The sequence for theFactor X protease cleavage site was introduced at the C-terminus ofNusA. The sequence for the AviTag (Avidity, Denver Colo.) biotinylationsite was introduced at the C-terminus of the chemokine coding sequence.The pET-derived plasmids were used for the co-transformation ofbacterial strain Origami B with pACYC184-BirA plasmid that encodes thebiotin ligase gene. For expression in mammalian cells, the gene encodingrelevant chemokines were cloned from cDNA in the pEAK8 expression vector(Edge Biosystems, Gaithersburg, Md.). An AviTag biotinylation site wasintroduced at the C-terminus of the protein followed by an internalribosome entry site (IRES) allowing for the expression of the BirA geneencoding a biotin ligase. This construct allows for the secretedexpression of chemokines biotinylated in vivo at a single site.

Expression of NusA-huRANTES Fusion Protein in E. coli

An overnight culture of bacteria harboring the expression construct wasdiluted 1:30 into Terrific broth (InvitroGen) containing 50 μg/mLAmpicillin, 10 μg /mL Kanamicin, 5 μg/mL Tetracycline, 20 μg/mLChloramphenicol and 50 μM Biotin. The culture was incubated at 37° C.with shaking until OD 600=0.7 was reached. IPTG was then added to afinal concentration of 1 mM, incubated for 15 min. at 37° C. andovernight at 25° C.

Expression of huRANTES in Mammalian Cells

PEAK cells were cultures in DMEM (Sigma) supplemented with 10% FCS, 2 mML-Glutamine (Sigma), 25 μg/ml gentamycin (Sigma) and incubated at 37°C., 5% CO₂. PEAK cells were transfected with the modified pEAK8 vectorsusing Mirus transfection reagent. Puromycin (Sigma) was added at 1 μg/mlafter cell adherence in order to select and maintain transfected cellpopulations. Biotin (Sigma) was added to production batches at 50 μM.Biotinylated chemokines from the transfected PEAK cell supernatants wereshown to be active in chemotaxis assays.

Purification and Cleavage of Fusion Proteins

Bacterial pellets were resuspended in Bugbuster (Novagen) containingBenzonase Nuclease and protease inhibitor Complete EDTA-free (Roche) andincubated for 1 hour at 4° C. The soluble and insoluble fractions wereseparated by centrifugation at 10,000 g for 15 min at 4° C. Soluble andinsoluble protein fractions were analyzed by SDS-PAGE (Novex gels,InvitroGen). The soluble fraction was diluted ½ with Buffer A (Tris-HCl100 mM pH 8.0, NaCl 600 mM, CaCl₂ 10 mM, Imidazole 40 mM), mixed with50% (v/v) Ni-NTA agarose (Qiagen) previously equilibrated in Buffer B(Tris-HCl 50 mM pH 8.0, NaCl 300 mM, CaCl₂ 5 mM, Imidazole 20 mM). Themixture was incubated for 30 min at RT with gentle shaking. The beadsobtained after centrifugation were loaded in Poly-Prep chromatographycolumns (Biorad), washed three times with 5 volumes of Buffer B andeluted with Buffer C (Tris-HCl 50 mM pH 8.0, NaCl 200 mM, CaCl₂ 5 mM,Imidazole 400 mM). Elution fractions containing the protein were pooledand desalted using PD-10 columns (Amersham). NusA-chemokine fusionproteins were cleaved by Factor X (Novagen, Madison, Wis.) by incubating1 mg protein with 25 U Factor X at 30° C. for up to 24 h in cleavagebuffer (Tris-HCl 50 mM pH 8.0, NaCl 200 mM , CaCl₂ 5 mM). For some ofthe fusions proteins, the parameters for optimal cleavage were slightlydifferent but were easily determined by varying incubation time (4-24h)and/or temperature (25-37° C.). The cleaved protein was analyzed bySDS-PAGE and the activity tested by chemotaxis.

Example 2 Screening of Human scFv Libraries

General procedures for construction and handling of human scFv librariesare described in Vaughan et al., (Nat. Biotech. 1996, 14:309-314),hereby incorporated by reference in its entirety. Libraries of humanscFv were screened against huRANTES according to the followingprocedure.

Liquid Phase Selections.

Aliquots of scFv phage libraries (10¹² Pfu) obtained from CambridgeAntibody Technology (Cambridge, UK) were blocked with PBS containing 3%(w/v) skimmed milk for one hour at room temperature on a rotary mixer.Blocked phage was then deselected on streptavidin magnetic beads (DynalM-280) for one hour at room temperature on a rotary mixer. Deselectedphage was then incubated with in vivo biotinylated huRANTES (100 nM) fortwo hours at room temperature on a rotary mixer. This selection step wasperformed either on NusA-huRANTES biotinylated fusion protein or onbiotinylated-huRANTES released from the fusion by proteolytic cleavage.Beads were captured using a magnetic stand followed by four washes withPBS/0.1% Tween 20 and 3 washes with PBS. Beads were then directly addedto 10 ml of exponentially growing TG1 cells and incubated for one hourat 37° C. with slow shaking (100 rpm). An aliquot of the infected TG1was serial diluted to titer the selection output. The remaining infectedTG1 were spun at 3000 rpm for 15 minutes and re-suspended in 0.5 ml2×TY-AG (2×TY media containing 100 μg/ml ampicilin and 2% glucose) andspread on 2×TYAG agar Bioassay plates. After overnight incubation at 30°C. 10 ml of 2×TYAG was added to the plates and the cells were scrapedform the surface and transferred to a 50 ml polypropylene tube. 2×TYAGcontaining 50% glycerol was added to the cell suspension to obtain afinal concentration of 17% glycerol. Aliquots of the selection roundwere kept at −80° C.

Phage Rescue.

100 μl of cell suspension obtained from previous selection rounds wereadded to 20 ml of 2×TYAG and grown at 37° C. with agitation (240 rpm)until an OD₆₀₀ of 0.3 to 0.5 was reached. The culture was thensuper-infected with 3.3×10¹⁰ MK13K07 helper phage and incubated for onehour at 37° C. (150 rpm). The medium was then changed by centrifugatingthe cells at 2000 rpm for 10 minutes, removing the medium andresuspending the pellet in 20 ml of 2×TY-AK (100 μg/ml ampicilin; 50n/ml kanamycin). The culture was then grown overnight at 30° C. (240rpm).

Monoclonal Phage Rescue for ELISA.

Single clones were picked into a microtiter plate containing 150 μl of2×TYAG media (2% glucose) per well and grown at 37° C. (100-120 rpm) for5-6h. M13KO7 helper phage was added to each well to obtain amultiplicity of infection (MOI) of 10 (i.e., 10 phage for each cell inthe culture) and incubated at 37° C. (100 rpm) for 1 h. Followinggrowth, plates were centrifuged at 3,200 rpm for 10 min. Supernatant wascarefully removed, cells re-suspended in 150 μl 2×TYAK medium and grownovernight at 30° C. (120 rpm). For the ELISA, the phage are blocked byadding 150 μl of 2× concentration PBS containing 5% skimmed milk powderfollowed by one hour incubation at room temperature. The plates werethen centrifuged 10 minutes at 3000 rpm and the phage containingsupernatant used for the ELISA.

Phage ELISA.

ELISA plates (Maxisorb, NUNC) were coated overnight with 2 μg/mlNusA-Rantes fusion protein in PBS. Control plates were coated with 2n/mlNusA. Plates were then blocked with 3% skimmed milk/PBS at roomtemperature for 1 h. Plates were washed 3 times with PBS 0.05% Tween 20before transferring the pre-blocked phage supernatants and incubationfor one hour at room temperature. Plates were then washed 3 times withPBS 0.05% Tween 20. 50 μl of 3% skimmed milk/PBS containing(HRP)-conjugated anti-M13 antibody (Amersham, diluted 1:10,000) to eachwell. Following incubation at room temperature for 1 hr, the plates werewashed 5 times with PBS 0.05% Tween 20. The ELISA was then revealed byadding 50 μl of TMB (Sigma) and 50 μl of 2N H₂SO₄ to stop the reaction.Absorption intensity was read at 450 nm.

Phage Clone Sequencing

Single clones were placed in a microtiter plate containing 150 μl of2×TYAG media (2% glucose) per well and grown at 30° C. (120 rpm)overnight. The next day 5 μl of culture was transferred into anotherplate containing 45 μl of dH₂O and mixed. The plates was then frozen at−20° C. After thawing, 1 μl of this suspension was used for PCRamplification using standard PCR protocols with primer specific forpCANTAB6: mycseq, 5′-CTCTTCTGAGATGAGTTTTTG-3′ (SEQ ID NO: 197) andgene3leader, 5′-TTATTATTCGCAATTCCTTTAGTTGTTCCT-3′ (SEQ ID NO: 198).

The PCR reactions were purified in 96 well format using the MontagePCRμ96 system (Millipore). 5 μl of the eluted DNA was sequencing usingthe mycseq and gene3leader primers.

ScFv Periplasmic Preparation for Functional Tests.

Individual clones were inoculated into a deep well microtiter platecontaining 0.9 ml of 2×TYAG media (0.1% glucose) per well and grown at37° C. for 5-6h (250 rpm). 100 μl per well of 0.2 mM IPTG in 2×TY mediumwere then added to give a final concentration of 0.02 mM IPTG. Plateswere then incubated overnight at 30° C. with shaking at 250 rpm. Thedeep-well plates were centrifuged at 2,500 rpm for 10 min and thesupernatant carefully removed. The pellets were re-suspended in 150 μlTES buffer (50 mM Tris/HCl (pH 8), 1 mM EDTA (pH 8), 20% sucrose,complemented with Complete protease inhibitor, Roche). A hypotonic shockwas produced by adding 150 μl of diluted TES buffer (1:5 TES:waterdilution) and incubation on ice for 30 min. Plates were then centrifugedat 4000 rpm for 10 minutes to remove cells and debris. The supernatantswere carefully transferred into another microtiter plate and kept on icefor immediate testing in functional assays or ELISAs.

Large Scale scFv Purification

A starter culture of 1 ml of 2×TYAG was inoculated with a single colonyfrom a freshly streaked 2×TYAG agar plate and incubated with shaking(240 rpm) at 37° C. for 5 hours. 0.9 ml of this culture was used toinoculate a 400 ml culture of the same media and was grown overnight at30° C. with vigorous shaking (300 rpm).

The next day the culture was induced by adding 400 μl of 1M IPTG andincubation was continued for an additional 3 hours. The cells werecollected by centrifugation at 5,000 rpm for 10 minutes at 4° C.Pelleted cells were resuspended in 10 ml of ice-cold TES buffercomplemented with protease inhibitors as described above. Osmotic shockwas achieved by adding 15 ml of 1:5 diluted TES buffer and incubationfor 1 hour on ice. Cells were centrifuged at 10,000 rpm for 20 minutesat 4° C. to pellet cell debris. The supernatant was carefullytransferred to a fresh tube. Imidazole was added to the supernatant to afinal concentration of 10 mM. 1 ml of Ni-NTA resin (Qiagen),equilibrated in PBS was added to each tube and incubated on a rotarymixer at 4° C. (20 rpm) for 1 hour.

The tubes were centrifuged at 2,000 rpm for 5 minutes and thesupernatant carefully removed. The pelleted resin was resuspended in 10ml of cold (4° C.) Wash buffer 1 (50 mM NaH₂PO₄, 300 mM NaCl, 10 mMimidazole, pH to 8.0). The suspension was added to a polyprep column(Biorad). 8 ml of cold Wash Buffer 2 (50 mM NaH₂PO₄, 300 mM NaCl, 20 mMimidazole, pH to 8.0) were used to wash the column by gravity flow. ThescFv were eluted from the column with 2 ml of Elution buffer (50 mMNaH₂PO₄, 300 mM NaCl, 250 mM imidazole, pH to 8.0). Fractions wereanalyzed by absorption at 280 nm and protein containing fractions werepooled before buffer exchange on a PD10 desalting column (Amersham)equilibrated with PBS. The scFv in PBS were analyzed by SDS-PAGE andquantified by absorption at 280 nm. The purified scFv were aliquoted andstored at −20° C. and at 4° C.

Example 3 Inhibition of huRANTES Induced Calcium Flux Using scFvExtracts

Periplasmic extracts of various huRANTES scFv were produced as describedabove. L1.2 cells expressing hCCR5 were cultured in RPMI mediumsupplemented with 10% FCS. Extracts containing the scFv were incubatedwith 2-10 nM of huRANTES (Peprotech, Rocky Hill N.J.) for 30 minutes atroom temperature. Cells were washed in PBS and loaded with 2 μM Fura2/AM. 100 μl of loaded cells were added to each well of a 96-well black,transparent flat-bottom plate and calcium flux kinetics were recorded bymeasuring the fluorescence at 514 nm upon excitation at 340 or 380 nm ona Flex station II instrument (Molecular Devices) upon addition of thechemokine scFv mix. The inhibitory activity of each scFv extract wasassessed by comparison to an extract containing an irrelevant scFv.

Example 4 scFv Inhibition of huRANTES-Induced Cell Chemotaxis

Wild type L1.2 cells and L1.2 cells expressing hCCR5 were cultured inRPMI medium supplemented with 10% FCS. The day before the experimentcells were incubated with 0.6 mg/ml of butyric acid. Differentconcentrations of purified scFv were incubated with 0.2-10 nM huRANTESand placed in the bottom chamber of chemotaxis 96-well plate(Neuroprobe). The filter plate was placed on top of the chemotaxis plateand each well was overlaid with 20 μl of a 10⁶ cells/ml suspension. Theplate was incubated for 2 hours at 37° C. Cells that migrated throughthe filter were stained with DRAQ5 (Alexis Corporation) and counted onan FMAT 8200 reader (Applied Biosystems, Foster City Calif.). The IC₅₀(where 50% of the huRANTES induced cell migration is inhibited, i.e.,50% inhibitory concentration), for each candidate antibody wasdetermined (Table 4).

TABLE 4 Potency of antibodies tested in scFv format in chemotaxisfunctional assays. Chemotaxis was performed using 1 nM, of huRANTES,Clone ID Chemotaxis IC₅₀ (nM) CG11 3.6 BG11 7 A9 72 E6 72 H6 25 G2 62E10 9.4 C10 41 2D1 1.3 A5 21 H11 4.3 D1 22 E7 3.8 C8 90 1D9 0.82 1E41.25 3E7 0.47 4D8 0.08 5E1 0.2 6A8 0.94 7B5 1.6

Example 5 Reformatting scFv into IgG Format

The V_(H) and V_(L) sequence of selected scFv were amplified withspecific oligonucleotides introducing a leader sequence and a HindIIIrestriction site at the 5′ end. An ApaI or an AvrII site was introducedat the 3′ end of the heavy and light chain sequence, respectively. Theamplified V_(H) sequences were digested HindIII/ApaI and cloned into thepCon_gamma1 expression vector (LONZA, Basel, Switzerland). The amplifiedV_(L) sequences were digested HindIII/AvrII and cloned into thepCon_lambda2 expression vector (LONZA). The constructions were verifiedby sequencing before transfection into mammalian cells.

The V_(H) and V_(L) cDNA sequences in their appropriate expressionvectors were transfected into mammalian cells using the Fugene 6Transfection Reagent (Roche, Basel, Switzerland). Briefly, Peak cellswere cultured in 6-well plates at a concentration of 6×10⁵ cells perwell in 2 ml culture media containing fetal bovine serum. The expressionvectors, encoding the candidate V_(H) and V_(L) sequences, wereco-transfected into the cells using the Fugene 6 Transfection Reagentaccording to manufacturer's instructions. One day followingtransfection, the culture media was aspirated, and 3 ml of freshserum-free media was added to cells and cultured for three days at 37°C. Following three days culture period, the supernatant was harvestedfor IgG purified on protein G-Sepharose 4B fast flow columns (Sigma, St.Louis, Mo.) according to manufacturer's instructions. Briefly,supernatants from transfected cells were incubated overnight at 4° C.with ImmunoPure (G) IgG binding buffer (Pierce, Rockford Ill.). Sampleswere then passed over Protein G-Sepharose 4B fast flow columns and theIgG consequently purified using elution buffer. The eluted IgG fractionwas then dialyzed against PBS and the IgG content quantified byabsorption at 280 nm. Purity and IgG integrity were verified bySDS-PAGE.

Example 6 Production of Native Human huRANTES

THP1 cells were cultured in 10 ml media at a concentration at 1×10⁶/mlwith 10 μg/ml LPS. Following overnight incubation at 37° C., cells werecentrifuged, supernatant was collected and the concentration of nativehuRANTES was estimated in a chemotaxis assay as described in Example 4.Not only native huRANTES but also other ligands of CCR5 are produced byTHP1 cells when stimulated with LPS as described above. Therefore, whenusing these supernatants in chemotaxis assays to determine theneutralization potential of anti-huRANTES antibodies, the other ligandsof CCR5 were neutralized with a mixture of antibodies against hMIP-1α,hMIP-1β, hMCP-2, hMIP-1δ each at a concentration of 5 μg/ml (R&DSystems).

Example 7 Inhibition of huRANTES-Induced Calcium Flux or Cell ChemotaxisUsing Reformatted scFv into IgG1 Format

scFv were reformatted into an IgG format as described above in Example5. The neutralizing potential of the IgG on huRANTES-induced calciumflux or cell chemotaxis was evaluated using the cell-based assaysdescribed in Example 3 and 4. As shown as examples in FIG. 1 IgGs C8,1D9 and 1E4 inhibit the activity of both recombinant and native huRANTESin a dose-dependent manner. The IC₅₀ values in these assays for allantibodies are summarized in Tables 5 and 6.

TABLE 5 Potency of antibodies tested in IgG1 format in chemotaxis andcalcium flux functional assays. Chemotaxis was performed using either1nM or 0.2 nM of recombinant huRANTES while calcium flux was inducedwith 10 nM of recombinant huRANTES. Chemotaxis Chemotaxis Calcium FluxIC₅₀ (nM) IC₅₀ (nM) IC₅₀ (nM) Clone ID 1 nM huRANTES 0.2 nM huRANTESrhuRANTES CG11 4.8 ND 9.5 BG11 29 ND 7.7 A9 1 ND 3.3 E6 14 ND 12.7 H68.7 ND 9 G2 18.4 ND ND E10 16 ND ND C10 17 ND ND 2D1 1.7 1.3 ND A5 13.2ND ND H11 1.3 ND ND D1 7 ND ND E7 2.2 ND ND C8 2.1 0.49 ND 1D9 0.350.038 ND 1E4 0.46 0.034 ND 3E7 0.68 0.25 ND 4D8 1.16 0.22 ND 5E1 0.820.25 ND 6A8 0.74 0.31 ND 7B5 1.1 0.31 ND

TABLE 6 Potency of antibodies tested in IgG1 format in chemotaxisfunctional assay performed using native human RANTES produced by THP1cells at a concentration of <1 nM. Chemotaxis IC₅₀ (nM) >1 nM nativeClone ID huRANTES C8 1.6 1D9 0.033 1E4 0.028

Example 8 Antibody Binding to huRANTES Immobilized on Glycosaminoglycan

As with many chemokines, huRANTES is able to oligomerize and bind toglycosaminoglycans (GAG) expressed at surface of cells such asendothelial cells. In order to make sure that the antibodies were ableto bind to huRANTES in this context, they were tested in the followingassay. Streptavidin coated 96 well plates (Roche, Basel, Switzerland)were coated with biotin labeled heparin as a prototypic GAG (Sigma, St.Louis, Mo.). After washing the excess heparin huRANTES was added thewells for immobilization GAG. After incubation with the antibodies to betested, the wells were washed and binding was revealed with ananti-human IgG Fcg specific antibody coupled to HRP (Jackson, WestGrove, Pa.). As shown in FIG. 2 some antibodies were able to bindhuRANTES when bound to GAG whereas others were unable to do so probablybecause their epitope on huRANTES was no longer accessible within theoligomeric structure. The capacity of the antibodies to bind huRANTES inthe context of GAG is summarized in Table 7.

TABLE 7 Ability of antibodies to bind to huRANTES immobilized on GAG.Binding to huRANTES Clone ID immobilized on GAGs CG11 No BG11 Yes A9 NoE6 Yes H6 No G2 Yes E10 Yes C10 Yes 2D1 Yes A5 Yes H11 No D1 No E7 No C8Yes 1E4 Yes 1D9 Yes

Example 9 Affinity Maturation of Antibody 2D1

A selected lead candidate (2D1) was subjected to affinity maturation inorder to increase its affinity for huRANTES and its potency in huRANTESneutralization assays. Stretches of 5 residues in the CDR3 of the heavyor light chain were randomized in order to generate 6 libraries (Librarysize ranging from 5×10⁷ to 10⁹). Three high stringency selection roundswere performed as described in Example 2. Screening for improved variantwas performed using scFv periplasmic extracts in an epitope competitionassay. Briefly, the parent antibody (2D1) was coated on plates anddiluted periplasmic scFv extracts were added to each well. BiotinylatedhuRANTES was then added and incubated for 2 hours at room temperature.After washing, huRANTES remaining bound to the coated parent antibodywas revealed using streptavidin coupled HRP (Jackson, West Grove Pa.).As a reference to identify improved variants 2D1 scFv was used tocompete coated 2D1 in an IgG format.

Example 10 Generation of a Stable CHOK1SV Cell Line Expressing 1E4

The CHOK1SV cell line, property of Lonza Biologics, plc, was used togenerate pools through semi-stable transfection for the production ofthe antibody 1E4. Briefly, exponentially growing cells in the mediumCD-CHO (Invitrogen) supplemented with 6 mM of L-glutamine, wereelectroporated under the following conditions: in a 0.4 cm cuvette,1.0×10⁷ viable cells in 700 μL of fresh CD-CHO were gently mixed with 40μg of DNA in 100 μL of Tris EDTA buffer solution, pH 7.4, immediatelyfollowed by delivering of a single pulse of 300 volts, 900 μF. Thecontents of 2 cuvettes were immediately transferred in 200 mL of freshpre-warmed CD-CHO medium. This cell suspension was subsequentlydistributed in 4 tissue culture-treated T75 flasks and placed in ahumidified incubator set at 10% CO₂ in air and a temperature of 37° C.to generate semi-stable pools. Around twenty-four hours aftertransfection, selective pressure (by MSX supplementation at 50 μM) wasapplied. Individual stably transfected clones were then selected usingClonePix technology (Genetix) and screened for 1E4 productivity.

Example 11 Large Scale Purification of 1E4 from CHO Supernatant

The process involves MabSelect SuRe affinity chromatography (GEHealthcare), retrovirus inactivation by low pH treatment, pH adjustmentfor SP Sepharose cation exchange chromatography,concentration/diafiltration before Capto Q (GE Healthcare) anionexchange chromatography and concentration/diafiltration into finalformulation buffer.

Briefly, supernatant produced by 25L Wave Bag fermentation of clone wasclarified and captured on MabSelect SuRe Protein A Affinity column withan overall recovery of 95% at 80% of the maximum loading capacity (32 mgof Antibody per mL of matrix). The eluate was proven to be stable atelution pH up to 48h. The stability of the 1E4 antibody was alsoevaluated at the low pH (3.7) used for viral inactivation and theAntibody was stable up to 48h.

The pool of Protein A eluates was then loaded onto an SP Sepharosecation exchange column after pH adjustment (pH 5).This step wasoptimised for efficient residual aggregate removal, the optimal elutionbuffer was found to be 107 mM Sodium Chloride (in 25 mM Sodium AcetatepH 5). A concentration/diafiltration step was then used to bufferexchange the 1E4 antibody into the appropriate buffer for Capto QChromatography (25 mM Sodium Acetate, 40 mM Sodium Chloride pH 5). Aconcentration of about 50 mg/mL was reached without any problems ofdegradation or aggregation. The Capto Q Chromatography in non-bindingmode was optimised for efficient contaminant removal (Host CellProteins, Protein A and DNA). Antibody 1E4 was finally concentrated anddiafiltered into the 25 mM Histidine, 125 mM NaCl, pH 6 formulationbuffer to a final concentration of about 10 mg/mL.

Antibody 1E4 did not show a tendency to aggregate throughout thepurification process, and presented good stability across thepurification process. The final product reached all prerequisitespecifications in terms of aggregates levels and residual contamination.

Example 12 Functional Characterization of Antibody 1E4 Purified form CHOSupernatant

RANTES is a ligand for the receptors CCR1, CCR3 and CCR5. The capacityof 1E4 purified from CHO supernatants to block the interaction with eachone of these receptors was assessed in chemotaxis and calcium fluxassays.

Calcium Flux

L1.2 cells expressing either hCCR1, hCCR3 or hCCR5 were cultured in RPMImedium supplemented with 10% FCS. For optimal results, cells expressinghCCR1 were starved overnight in medium containing 1% of FCS. The daybefore the experiment all cells were incubated with 0.3 mg/ml of butyricacid. Different concentrations of 1E4 were incubated with 4 to 25 nM ofhuRANTES (Peprotech, Rocky Hill NJ) for 30 minutes at room temperature.Cells were washed in PBS and loaded with 2 μM Fura 2/AM. 100 μl ofloaded cells were added to each well of a 96-well black, transparentflat-bottom plate and calcium flux kinetics were recorded by measuringthe fluorescence at 514 nm upon excitation at 340 or 380 nm on a Flexstation II instrument (Molecular Devices) after addition of thechemokine-antibody mix. As shown in FIG. 3, 1E4 was able to inhibitcalcium flux in cells that express either hCCR1, hCCR3 or hCCR5 in adose dependent manner. The IC₅₀ (where 50% of the huRANTES inducedcalcium flux is inhibited, i.e., 50% inhibitory concentration) wasdetermined (Table 8).

TABLE 8 Potency of antibody 1E4 purified from CHO supernatant in calciumflux functional assay using cells expressing the one three cognatereceptors of RANTES. Cells and concentration of huRANTES IC₅₀ used forcalcium flux induction (nM) L1.2-hCCR1; 25 nM huRANTES 4.9 L1.2-hCCR3;25 nM huRANTES 4.46 L1.2-hCCR5; 4 nM huRANTES 0.54Chemotaxis

Wild type L1.2 cells and L1.2 cells expressing either hCCR1, hCCR3 orhCCR5 were cultured in RPMI medium supplemented with 10% FCS. Foroptimal results, cells expressing hCCR1 were starved overnight in mediumcontaining 1% of FCS. The day before the experiment all cells wereincubated with 0.3 mg/ml of butyric acid. For optimal results, cellsexpressing hCCR1 were starved overnight in medium containing 1% of FCS.Different concentrations of 1E4 were incubated with 1-10 nM ofrecombinant huRANTES or 1 nM of native huRANTES (generated as describedin example 6) and placed in the bottom chamber of chemotaxis 96-wellplate (Neuroprobe). The filter plate was placed on top of the chemotaxisplate and each well was overlaid with 20 μl of a 10⁶ cells/mlsuspension. The plate was incubated for 2 hours at 37° C. Cells thatmigrated through the filter were stained with DRAQ5 (Alexis Corporation)and counted on an FMAT 8200 reader (Applied Biosystems, Foster CityCalif.). As shown in FIG. 4, 1E4 was able to inhibit calcium flux incells that express either hCCR1, hCCR3 or hCCR5 in a dose dependentmanner. The IC₅₀ (where 50% of the huRANTES induced cell migration isinhibited, i.e., 50% inhibitory concentration) was determined (Table 9).

TABLE 9 Potency of antibody 1E4 purified from CHO supernatant inchemotaxis functional assay using cells expressing the one three cognatereceptors of RANTES. Cells and concentration of huRANTES IC₅₀ used forchemotaxis assays (nM) L1.2-hCCR1; 2 nM huRANTES 0.46 L1.2-hCCR3; 10 nMhuRANTES 3.33 L1.2-hCCR5; 1 nM huRANTES 0.2 L1.2-hCCR5; 1 nM nativehuRANTES 0.09

Example 13 Cross-Reactivity of 1E4 Antibody

1E4 was tested for its ability to bind to a panel of chemokines fromdifferent species in an ELISA. The panel included the followingchemokines: human RANTES, cynomolgus monkey RANTES, rat RANTES, mouseRANTES, human ITAC, human IP-10, cynomolgus monkey IP-10, human MIG,cynomolgus monkey MIG, human MIP1α, human MIP1β, human MCP-1, humanMCP-2. Briefly, chemokines cloned from cDNA isolated from human, mouse,rat, and cynomolgus monkey were expressed as fusion proteins andpurified as described in Example 1. The chemokines were coated at 5μg/ml in an maxisopb plate (Nunc, Denmark) and incubated with aconcentration range of 1E4. The level of binding was revealed using ananti-human Fc-γ specific antibody coupled to horse radish peroxidase(Jackson) and a fluorescent substrate. As shown in FIG. 5, the antibody1E4 only binds to human and cynomolgus RANTES and not with RANTES fromother species nor with any of the other human chemokines tested. Propercoating of all the chemokines was controlled using monoclonal antibodiesdirected against each chemokine and all the chemokines tested could bedetected in this format.

Example 14 Epitope Mapping of 1E4 Antibody

In an ELISA, the antibody 1E4 binds with equivalent apparent affinity toboth human and cynomolgus RANTES (FIG. 5). In order to identify residuespotentially required on huRANTES for binding to 1E4, the RANTES proteinsequences from several species were aligned as shown in FIG. 6. In thealignment, residues that are conserved between the human and cynomolgussequences and that are different in mouse and rat RANTES to which 1E4 isunable to bind were analyzed to identify the following amino acids: A16,R17, P18, G32, P37, R59 and S64. Three mutants of mouse RANTES weregenerated by site directed mutagenesis in order to introduce the humanresidues at those positions: [S16A/L17R/A18P]; [S32G/L37P] and[Q59R/Y64S]. These mutant forms of mouse RANTES were expressed andbiotinylated in vivo as described in Example 1. These variant of mouseRANTES were captured in streptavidin coated plates (Streptawell, Roche).The coating of the biotinylated chemokine was confirmed using aanti-mouse RANTES polyclonal antibody (R&D Systems). It was then testedwhether the introduction of these residues could restore 1E4 binding tomouse RANTES. Briefly, mouse RANTES, human RANTES as well as threemutant forms of mouse RANTES and control supernatants were captured inStreptawell plates (Roche) for 30 minutes at room temperature. Afterwashing, antibody 1E4 was added at a concentration of 1 μg/ml in 1%BSA-PBS and incubated for 1 hour at room temperature. The plate waswashed and incubated with a goat anti-human IgG Fcγ-specific antibodycoupled to horse radish peroxidase (Jackson). After washing the signalwas revealed with TMB (Roche) and stopped with H₂SO₄. The plates wereread at 450 nm. As shown in FIG. 7, the [S16A/L17R/A18P]mutant restoresbinding of 1E4 to mouse RANTES indicating that A16, R17 and P18 arecritical for the 1E4 epitope integrity on human RANTES.

Example 15 Affinity and Binding Kinetics of 1E4

The affinity and binding kinetics of 1E4 on human RANTES and cynomolgusRANTES were characterized on a Biacore 2000 instrument (Biacore AB,Uppsala, Sweden). 433 RU (response unit) of a donkey anti-human IgGpolyclonal antibody were immobilized by EDC/NHS chemistry on a C1Biacore chip. This surface was used to capture antibody 1E4. The surfacewas regenerated after each cycle by injection of 10 mM glycine pH=2 at30 μL/min, for 60s followed by 1 min. of stabilization time in HBS-EPbuffer.

Binding was measured by passing either huRANTES (Peprotech, Rocky HillNJ) or a NusA-fusion proteins of human RANTES (NusA-huRANTES) andCynomolgus RANTES (NusA-cynoRANTES) at various concentrations. Allproteins were diluted in the running buffer HBS-EP buffer (Biacore AB,Uppsala, Sweden). Injection was performed at 75 μl/min for 3 min.followed by 15 min. of dissociation time and the temperature was set at25° C. The data was fitted according to 1:1 Langmuir model and theK_(on), K_(off) and K_(D) values determined. Very similar values wereobtained using huRANTES or the NusA-huRANTES fusion, but better responsesignals were obtained with the fusion protein due to its larger sizethat induces a better response on the Biacore. The affinity of antibody1E4 for huRANTES and cynoRANTES are 0.45 nM and 2.24 nM, respectively.The Affinities and kinetic constants of both antibodies are summarizedin Table 10.

TABLE 10 Kinetic and affinity constants of antibody 1E4 for human andcynomolgus RANTES measured by Biacore. huRANTES NusA-huRANTESNusA-cynoRANTES Ka (1/Ms) 5.36 × 10⁶ 1.87 × 10⁶ 5.46 × 10⁶ Kd (1/s) 2.44× 10⁻³ 8.35 × 10⁻⁴ 1.22 × 10⁻³ KD (M) 4.55 × 10⁻¹⁰ 4.47 × 10⁻¹⁰ 2.24 ×10⁻⁹

Example 16 Animal Model of Ischemia

Materials and Methods

Animals: Eight to 12 week old C57BL/6 mice are used for the experiments.All animal studies were approved by the local ethical Committee.

Antibodies and in vivo treatment: C57BL/6 mice were injected either inthe peritoneal cavity (i.p.) or intraveneously (i.v.). For the ischemiafollowed by reperfusion model, monoclonal antibodies (mAb) were injected5 minutes before the end of the occlusion period. For the permanentligation model, mAbs were injected 5 minutes after the chronic ligaturewas put in place. The mAbs included: (1) the rat anti-mouse RANTES(mRANTES), mAb478 and (2) the rat anti-mouse isotype mAb control, mAb64.Hybridomas that produced mAb478 or mAb64 were obtained from R&D or theAmerican Tissue Culture Collection, respectively, and all mAb wereproduced, purified and stored in-house.

For the i.p. treatment, 1 mg/mouse of the IgG control or anti-mRANTESmAbs was administered. For the i.v. treatment, either 0.1, 0.3, 0.5 or 1mg/mouse of the anti-mRANTES mAb or 1 mg/mouse of the IgG control (i.e.highest dose of anti-mRANTES) was administered.

In vivo Ischemia-Reperfusion or Ligation Permanent Model

Surgery: Mice were initially anesthetized with 4% isofluorane thenintubated. Mechanical ventilation was performed with a tidal volume of300 μL at 120 breaths using a rodent respirator (model 683; HarvardApparatus). Anesthesia was maintained with 2% isofluorane delivered 100%through the ventilator. A thoracotomy was performed in the left fourthintercostal space, and the pericardial sac was then removed. An 8-0Prolene suture was passed under the left coronary artery at the inferioredge of the left atrium and tied with a slipknot to produce occlusion.

For the reperfusion model, a small piece of polyethylene tubing was usedto secure the ligature without damaging the artery and after 30 minutesof ischemia, the left anterior descending (LAD) coronary arteryocclusion was released and reperfusion permitted to occur.

For the permanent legation model, the LAD coronary artery wasirreversibly occluded by using a double knot 8-0 Prolene suture. Thechest was then closed and air was evacuated from the chest cavity. Theendotracheal tube was then removed and normal respiration restored.

After 24 hours of reperfusion or after 24 hours of permanent occlusion,animals were euthanized to determine infarct size.

Evaluation of Risk Zone and Infarct Size: At the end of the reperfusionperiod, mice were re-anesthetized with 0.3 mL ketamine-xylazine and theLAD coronary artery was re-ligated. 3% Evans Blue dye (Sigma) wasinjected i.v. (retro-orbital administration) to delineate the in vivorisk zone (R). The heart was rapidly excised and rinsed in saline. Afterremoval of the right ventricle and connective tissues, the heart wasfrozen and then sectioned into 3-mm transverse sections from apex tobase (5 slices/heart). Following thawing, the sections were incubated at37° C. with 1% triphenyltetrazolium chloride in phosphate buffer (pH7.4)for 15 min, fixed in 10% formaldehyde solution and, after 24 hours,photographed with a digital camera to distinguish areas of stainedviable versus unstained necrotic tissue. Left ventricular infarct zone(I) was determined using a computerized planimetric technique(MetaMorph6 software, Zeiss) and expressed as a percentage of either thearea at risk (AAR) or ventricular area (V).

Example 17 Effect of Inhibiting RANTES in Ischemia Reperfusion Models

Model 1: Ischemia Reperfusion

A diagram illustrating the protocol of the murine ischemia reperfusionmodel is shown in FIG. 8. In this protocol, B6 mice are divided intothree groups and administered a vehicle control (PBS), an isotypecontrol (mAb 64 described in Example 10) or a rat anti-mRANTESmonoclonal antibody according to the following schedule:

-   -   Group 1: PBS administered i.p. or i.v. 5 minutes prior to        reperfusion;    -   Group 2: rat IgG2a (mAb 64; isotype control) administered i.p.        (1 mg/mouse) or i.v. (1.0 mg/mouse) 5 minutes prior to        reperfusion;    -   Group 3: rat anti-mouse RANTES (mAb 478) administered i.p. (1        mg/mouse) or i.v. (0.1, 0.3, 0.5, 1.0 mg/mouse) 5 minutes prior        to reperfusion;

All animals were killed 24 hours post-reperfusion. Each group of micewas evaluated by assessing the following parameters:

-   -   weight of mice;    -   AAR/V=area at risk divided by the total area of heart (ischemic        zone);    -   I/AAR=infarcted area divided by the area at risk; and    -   I/V=infarcted area divided by the total area of the ventricles.

Both I/AAR and I/V provide data on extent of infarcted tissue.

As shown in FIG. 9, treatment with the anti-RANTES monoclonal antibodydecreased infarct size in the murine model of ischemia reperfusionprovided herein. Injecting mAb 478 (1 mg/mouse i.p.) five minutes priorto reperfusion significantly decreased the infarct size as compared toisotype control or PBS treated mice. Data represents 20 mice per group.

FIG. 10 demonstrates that treatment with the anti-RANTES monoclonalantibody decreased infarct size in the murine model of ischemiareperfusion in a dose-dependent manner. Injecting mAb 478 i.v. (at dosesof 0.1, 0.3, 0.5, 1.0 mg/mouse) five minutes prior to reperfusionsignificantly decreased the infarct size at higher doses as compared toisotype control (1 mg/mouse). Data represents 3 mice per group.

Model 2: Permanent Occlusion

A diagram illustrating the protocol of the murine permanent occlusionmodel is shown in FIG. 11. In this protocol, B6 mice are divided intothree groups and administered a vehicle control (PBS), an isotypecontrol (mAb 64 described in Example 10) or a rat anti-mRANTESmonoclonal antibody according to the following schedule:

-   -   Group 1: PBS administered i.p. or i.v.;    -   Group 2: rat IgG2a (mAb 64; isotype control) administered i.p.        (1 mg/mouse) or i.v. (1.0 mg/mouse);    -   Group 3: rat anti-mouse RANTES (mAb 478) administered i.p. (1        mg/mouse) or i.v. (0.1, 0.3, 0.5, 1.0 mg/mouse).

Each group of mice was evaluated by assessing the following parameters:

-   -   weight of mice;    -   AAR/V=area at risk divided by the total area of heart (ischemic        zone);    -   I/AAR=infarcted area divided by the area at risk; and    -   I/V=infarcted area divided by the total area of the ventricles .

All animals were killed at 24 hrs post occlusion.

As shown in FIG. 12, treatment with the anti-RANTES monoclonal antibodydecreased infarct size in the murine model of ischemia provided herein.Injecting mAb 478 (1 mg/mouse i.p.) significantly decreased the infarctsize as compared to isotype control or PBS treated mice. Data represents10 mice per group.

FIG. 13 demonstrates that treatment with the anti-RANTES monoclonalantibody decreased infarct size in the murine model of ischemia in adose-dependent manner. Injecting mAb 478 i.v. (at doses of 0.1, 0.3,0.5, 1.0 mg/mouse) significantly decreased the infarct size at higherdoses as compared to isotype control (1 mg/mouse). Data represents 3mice per group.

Other Embodiments

While the invention has been described in conjunction with the detaileddescription thereof, the foregoing description is intended to illustrateand not limit the scope of the invention, which is defined by the scopeof the appended claims. Other aspects, advantages, and modifications arewithin the scope of the following claims.

What is claimed is:
 1. An isolated fully human monoclonal antibody orfragment thereof that binds human Regulated upon Activation, NormalT-cell Expressed, and Secreted (RANTES), wherein said antibodycomprises: (a) a V_(H) CDR1 region comprising the amino acid sequence ofSEQ ID NO: 8; (b) a V_(H) CDR2 region comprising the amino acid sequenceof SEQ ID NO: 9; (c) a V_(H) CDR3 region comprising the amino acidsequence of SEQ ID NO: 10; (d) a V_(L) CDR1 region comprising the aminoacid sequence of SEQ ID NO: 14; (e) a V_(L) CDR2 region comprising theamino acid sequence of SEQ ID NO: 15; and (f) a V_(L) CDR3 regioncomprising the amino acid sequence of SEQ ID NO: 16, wherein saidantibody binds RANTES.
 2. The antibody of claim 1, wherein said antibodyis an IgG isotype.
 3. The antibody of claim 1, wherein said antibody isan IgG1 isotype.
 4. The antibody of claim 1, wherein said antibodyfurther comprises a heavy chain variable sequence comprising the aminoacid sequence of SEQ ID NO: 2 and a light chain variable sequencecomprising the amino acid sequence of SEQ ID NO:
 4. 5. A pharmaceuticalcomposition comprising the antibody of claim 1 and a carrier.
 6. Anisolated fully human monoclonal antibody comprising a heavy chainvariable sequence comprising the amino acid sequence of SEQ ID NO: 2 anda light chain variable sequence comprising the amino acid sequence ofSEQ ID NO: 4, wherein said antibody binds RANTES.
 7. The antibody ofclaim 6, wherein said antibody is an IgG isotype.
 8. The antibody ofclaim 6, wherein said antibody comprises a heavy chain sequencecomprising the amino acid sequence of SEQ ID NO: 167 and a light chainsequence comprising the amino acid sequence of SEQ ID NO:
 168. 9. Anisolated antibody that binds human Regulated upon Activation, NormalT-cell Expressed, and Secreted (RANTES) when human RANTES is bound to aglycosaminoglycan (GAG), wherein said antibody comprises: (a) a V_(H)CDR1 region comprising the amino acid sequence of SEQ ID NO: 8; (b) aV_(H) CDR2 region comprising the amino acid sequence of SEQ ID NO: 9;(c) a V_(H) CDR3 region comprising the amino acid sequence of SEQ ID NO:10; (d) a V_(L) CDR1 region comprising the amino acid sequence of SEQ IDNO: 14; (e) a V_(L) CDR2 region comprising the amino acid sequence ofSEQ ID NO: 15; and (f) a V_(L) CDR3 region comprising the amino acidsequence of SEQ ID NO:
 16. 10. The antibody of claim 9, wherein saidantibody is a monoclonal antibody or an antigen-binding fragmentthereof.
 11. The antibody of claim 9, wherein said antibody is a fullyhuman monoclonal antibody or an antigen-binding fragment thereof. 12.The antibody of claim 9, wherein said antibody is an IgG isotype. 13.The antibody of claim 9, wherein said antibody is an IgG1 isotype.